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ABSTRACT 
 
Diabetes mellitus is a disease that affects the regulation of a person’s blood 
glucose levels. Fully implantable continuous glucose monitoring (CGM) has the 
potential to improve diabetes management by improving patient compliance and more 
importantly, providing patients with a more detailed trend of their glucose level on a 
daily basis. One such approach in the development of a CGM device is the use of the 
lectin Concanavalin A (ConA) in a competitive glucose binding assay. The current set 
back to these ConA based assay has to do with its stability, and sensitivity. Furthermore, 
current CGM devices face longevity issues due to the nature of the implant and attack 
from the immune system. 
Therefore, the overall goal of the project is to develop a fully implantable, 
minimally invasive CGM device that would overcome issues pertaining to longevity, 
stability and sensitivity. Towards this goal, the current work aimed to first develop a 
non-aggregative thermally stable glucose sensing assay. First, ConA’s thermal stability 
at body temperature (37 oC) was evaluated and based on the resulting instability, ConA 
was modified with poly (ethylene glycol) chains to improve its thermal stability at 37 oC. 
Results showed that the presence of these PEG chains improved ConA’s thermal 
stability without significantly hindering its ability to bind to a competing ligand and 
sense changes in glucose concentrations within the physiologically relevant range. 
Next, this worked characterized the sensitivity and FRET efficiency of the newly 
modified ConA based assay, paired with the recently introduced monovalent competing 
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ligand, mannotetraose.  These characteristics was compared to current traditional 
ConA/dextran based glucose sensing assay. It was determined that across the desired 
glucose concentration range of 0 to 600 mg/dL, the new PEGylated 
ConA/mannotetraose based assay had improved sensitivity and FRET efficiency when 
compared to a PEGylated ConA/dextran based assay. 
Finally, this work aimed to encapsulate the modified assay within the proposed 
biocompatible membrane, PNIPAAm, and evaluate its ability to sense changes in 
external glucose concentration. To accomplish this, different encapsulation techniques 
such as calcium carbonate microspheres, alginate microspheres and layer by layer (LbL) 
deposition on PNIPAAm copolymer AMPS (AMPS-PNIPAAm) hydrogels were 
investigated to achieve minimal leaching without significantly impacting the glucose 
sensing of the assay within a hollow rod shaped membrane. The work also investigated 
the modification of the assay to increase the size of the smaller assay component as an 
alternative means to try and retain the assay within the biocompatible membrane. The 
deposition of LbL on the inner wall of the AMPS-PNIPAAm rods proved to be more 
efficient with an approximate 50% change in FRET signal for changes in glucose 
concentration ranging from 0 to 600 mg/dL and a mean absolute relative difference 
(MARD) of ~10%.  
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NOMENCLATURE 
 
AMPS 2-Acrylamido-2-Methylpropane Sulfonic Acid 
APTS 8-Aminopyrene-1,3,6-Trisulfonic Acid 
CGM Continuous Glucose Monitoring 
CL Competing Ligand 
ConA Concanavalin A 
DLS Dynamic Light Scattering 
DN Double Network 
FA Fluorescence Anisotropy 
FITC Fluorescein Isothiocyanate 
FRET Forster Resonance Energy Transfer 
LbL Layer-by-Layer 
mPEG Methoxyl-Poly (Ethylene Glycol) 
MT Mannotetraose 
MARD Mean Absolute Relative Difference 
MW Molecular Weight 
PAH+ Poly (Allylamine) 
PDADMAC+ Poly (Diallyldimethylammonium Chloride) 
PEG Poly (Ethylene Glycol) 
PNIPAAm Poly (N-isopropylacrylamide) 
PSS- Poly (Sodium 4-Styrenesulfonate) 
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RT Room Temperature 
TRITC Tetramethylrhodamine Isothiocyanate 
wt% Weight Percent 
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CHAPTER I  
INTRODUCTION AND BACKGROUND REVIEW* 
Diabetes 
The carbohydrate molecule, glucose is an important source of nutrient within the 
body. Therefore, its physiological concentration level needs to be maintained in order for 
most biological processes to function properly. However, for approximately 29 million 
people within the United States (U.S.) and over an estimated 300 million worldwide, 
their bodies are unable to properly regulate and maintain its glucose level within the 
normal range of 80 mg/dL to 130 mg/dL.1, 2 This is known as the disease Diabetes 
mellitus and it is largely related to problems surrounding the production and regulation 
of the insulin hormone. 
There are three classes or types of this disease, Type I (Juvenile Diabetes), Type 
II, and Gestational diabetes. Type I is due to the body’s inefficiency to produce insulin 
because of destruction to the beta cells of the pancreas.3 It is typically diagnosed during 
childhood and affects an estimated five percent of the U.S. population. Type II, is the 
most common form of Diabetes, where the body does not produce enough insulin or 
does not use it properly.3 Gestational diabetes is linked to pregnancy where it is assumed 
that due to the rise in hormonal levels, typically around 24 weeks, there is a disruption of 
* Part of this chapter is reprinted with permission from A.K. Locke, B. M. Cummins, A. A. Abraham and 
G. L. Coté. “ PEGylation of Concanavalin A to Improve Its Stability for an In Vivo Glucose Sensing 
Assay,” Analytical Chemistry 2014, 85(11), 5397-5404. Copyright 2014 American Chemical Society; and 
from A.K. Locke, B. M. Cummins, and G. L. Coté. “High Affinity Mannotetraose as an Alternative to 
Dextran in ConA Based Fluorescent Affinity Glucose Assay Due to Improved FRET Efficiency,” ACS 
Sensors 2016, 1 (5), 584-590. Copyright 2016 American Chemical Society. 
  
2 
 
the mother’s use of insulin.3 In each of these cases, if normal physiological glucose 
concentration is not maintained the outcome can be very detrimental to the patient’s 
health. The advent of low physiological glucose concentration (hypoglycemia) may 
result in coma and/or death, while high glucose concentrations (hyperglycemia) can 
cause long term, secondary complications. These complications include kidney failure, 
gangrene leading to amputations, heart disease and nerve damage. These secondary risks 
have a tremendous impact on the quality of life of patients and the cost of their 
healthcare expenditure.4 Therefore, there is a need for patients to tightly monitor their 
glucose level in order to treat any deviations through insulin injections, diet, and/or 
exercise.  
 
History of Glucose Monitoring 
The first generation of devices designed to monitor physiological glucose were 
qualitative urine tests. In 1941, Bayer introduced Clinitest®,  an alkaline copper sulphate 
reagent tablet which changed color from green to orange with increasing concentration 
of glucose.5 In the 1950s and 1960s, glucose test tapes/strips such as “Tes-Tape”, 
“Dipstix” and “Diastix” were introduced. These test strips are able to indirectly detect 
glucose via an enzymatic reaction involving glucose oxidase which is immobilized on 
tip of these strips. If glucose is present, the strip also changed color corresponding to an 
estimated glucose concentration.  
Although these devices are low cost and painless the major drawbacks are their 
failure to detect hypoglycemia and difficulty in interpreting the colorimetric changes. 
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Therefore, the second generation devices were developed to be more accurate 
and provide a quantitative methodology for self-monitoring of the glucose level within 
the blood. These devices include the well-known “finger-prick” test using a glucometer. 
The Ames Reflectance Meter was the first glucometer developed in the 1970s by Anton 
Clemens.6 This device utilized the enzymatic reagent blood test strip, Dextrostix which 
required a small droplet of blood that was washed away after one minute. The glucose 
within the blood, in the presence of oxygen, reacted with the immobilized GOx. One of 
the by-product, hydrogen peroxide, then reacted with a reducing dye on the test strip 
which changed color. The reflectance meter then shined a light on the test strip and the 
reflected light is analyzed to provide a quantitative value correlating to glucose 
concentration. The darker the color change, due to higher glucose concentration, the less 
light reflected back. However it was reported that the device became unstable and 
inaccurate above 180 mg/dL.7  Since this development, there have been numerous 
improvement on the design including portability, use of electrochemical sensor to 
improve sensitivity and accuracy, elimination of the blood removal step, reduction in the 
required volume of blood and faster testing time.8 
To date, this “finger prick” test is the most common way that patients self-
monitor their glucose level. It is recommended that measurements be taken at least five 
times per day. However, this method which requires the repetitive puncture of the skin 
results in low patient compliance. Furthermore, because this test only provides a few 
time points of the patient’s glucose level, they may be unaware of times when they are 
approaching or are already experiencing critical levels. This has lead researchers and 
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several medical device companies to investigate new ways in developing next generation 
devices categorized as “continuous glucose monitoring” device in order to overcome the 
current problem associated with the finger-prick method. 
Third generation devices are geared towards continuous glucose monitoring 
(CGM), non-invasively or minimally invasive, which have the potential to provide 
patients the necessary information for them to be able to better manage their glucose 
level. These devices involve using different optical techniques such as Fluorescence 
spectroscopy, Near Infrared spectroscopy, Raman spectroscopy, and Polarimetry.9-11  
Currently, there are only a few commercially available CGM devices approved 
by the Food and Drugs Administration (FDA). These devices include: (1) DexcomTM G4 
Platinum (7 days lifetime), (2) DexcomTM SEVEN Plus (7 days lifetime), and (3) 
MiniMed Guardian® (3 days lifetime) by Medtronic.  Each device display and record 
data in five min intervals and have the ability to alert patients when they are approaching 
hypoglycemic or hyperglycemic levels. However, their need for frequent calibration via 
the “finger prick” test, weekly replacement due to limited lifetimes, as well as their 
transdermal sensor component which cause skin irritation limits the wide impact that 
these devices can have in the monitoring of the disease. Thus, there is still a need to 
develop new sensors that do not require frequent calibration and can be fully implanted 
or integrated non-invasively to improve on the longevity of the devices. 
Herein, this work focused on the design of a fully implantable fluorescence based 
CGM devices because of its potential to achieve higher sensitivity to glucose over the 
other techniques. 
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Fluorescence Based Continuous Glucose Monitoring  
When a molecule absorbs energy its electron is excited to a higher energy level, 
upon return to its ground state it emits a photon and this phenomenon is known as 
fluorescence. Generally, the emitted light occurs at a longer wavelength than the excitation 
light. This emission can be isolated using filters and measured using a photo-detector.  
Fluorescence based sensors are advantageous because of they are highly sensitive and 
have known to be very favorable to molecular based detection due to its high signal to 
noise ratio.12 As a result, fluorescence has been greatly used as the basis for glucose 
sensing. Fluorescence based glucose sensors generally involve systems that utilizes energy 
transfer, the monitoring of enzymatic consumption or intrinsic fluorescence and measures 
either the fluorescence intensity or lifetime of the fluorophore. Three most common 
fluorescence based glucose sensors: (1) glucose oxidase based assays, (2) boronic acid 
derivatives, and (3) Concanavalin A competitive assay are discussed in this section. 
 
Glucose Oxidase Based Sensors 
Enzymes are commonly used as sensor components to indirectly track different 
biological analyte because of their high specificity. In terms of glucose sensing, Glucose 
oxidase (GOx) is the most common enzyme used. Because this is an indirect reaction 
resulting in the production of gluconic acid and hydrogen peroxide as by-products, 
glucose can indirectly be monitored in three different ways: (1) by measuring the 
changes in pH due to gluconic acid formation, (2) measuring the hydrogen peroxide 
produced, and (3) measuring the oxygen consumed.  Although specific, enzymatic based 
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sensing relies on a stable, controllable environment. This becomes problematic in vivo 
affecting the sensitivity and stability of the sensors.  
 
Boronic Acid Derivative Sensors 
Boronic acid covalently binds to 1,2-or 1,3-diols and results in a cyclic ester 
bond.13 This binding is reversible and has led to the use of boronic acid as a sensor. 
Furthermore, boronic acid contains a six carbon ring and as a result exhibits fluorescence 
properties. However, the excitation and emission wavelengths are short, 200 to 350 nm 
excitation and 400 to 500 nm emission range which limit its physiological usage. Yoon 
and Czarnik first proposed an anthyrlboronic acid based sensor for carbohydrate sensing. 
Anthyrlboronic acid when in water can fluorescently emit around 416 nm upon 
excitation.14 When the pH of its environment becomes more basic, the fluorescence 
intensity decreased and Yoon et al suggested that this change maybe due to Chelation 
Enhanced Quenching. When carbohydrates such as fructose were introduced, it was 
noted that the intensity decreased as the pKa of the system was approximately 8.8.
14 It is 
important to note that this fluorescence sensor showed a higher sensitivity to fructose 
than glucose but it was the first reported study which showed that boronic acid 
derivatives may be used for the sensing of carbohydrates. Since this study many 
researchers have studied the use of boronic acid derivatives as potential glucose sensors. 
Each of these fluorescence based sensors have shown potential for use as a CGM 
device. Herein, this work focus on ConA based CGM devices since it does not consume 
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glucose, it’s stable within physiological pH and it can easily be labelled with a fluorophore 
that can be interrogated in vivo. 
 
Concanavalin A Based Sensors 
Concanavalin A (Con A) is a lectin which binds to carbohydrates and is derived 
from jack bean. Under certain pH conditions it takes on either a dimeric (pH <7) or 
tetrameric (pH>7) conformation.15, 16 In order to bind to glucose, manganese ions (Mn2+) 
and calcium ions (Ca2+) needs to be present to activate the binding site. However, because 
ConA is not selective to which carbohydrate it binds to, the binding association of the 
carbohydrate in relation to ConA is important. For example, ConA has a higher binding 
affinity to α-D-glucose than β-D-glucose. Therefore ConA based sensors typically 
involves a competitive displacement of a molecule in the presence of another which has a 
higher binding affinity to ConA.  ConA based glucose sensors are favorable because 
unlike the enzymatic sensors, they do not require the consumption of glucose to provide 
information about the concentration of glucose that is present.  However, the toxicity of 
the lectin has been questioned but recent studies have shown that if ConA does leach out 
of the sensor, the concentration is not significant to cause harm.17 Herein, the three most 
common ConA based sensors are discussed in this section. 
 
Con A and Dextran 
The most researched competitive assay sensor is comprised on ConA and 
fluorescently labeled dextran. Dextran is a polysaccharide that has a binding affinity to 
ConA that varies based on its molecular weight (MW).   In 1982, Schultz, Mansouri and 
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Goldstein pioneered a technique for developing implantable sensors for glucose using 
ConA and fluorescein-labeled dextran (FITC dextran).18 This approach was based on the 
competitive displacement of dextran, from ConA binding sites, in the presence of glucose 
and the measurement of the unbound FITC-dextran to determine an approximate 
concentration of glucose present. Since this introduction, many researchers have tried to 
improve the sensitivity of ConA/dextran based sensors. 
Furthermore, there are now several companies developing CGM devices based on 
this technology to achieve improved sensitivity, accuracy, and working lifetime. Also, 
more recently research conducted by Ballerstadt et al. have led to the development of a 
fiber coupled CGM device, currently under license with BioTex Inc. as a second 
generation Fluorescence Affinity Sensor (FAS).19 In vivo human studies recently 
conducted on this device showed a mean absolute relative error of 13% over a period of 4 
hours.20 In addition, Muller et al. in 2013 introduced another fiber coupled CGM device 
called FiberSense.21 This device showed improved MARD percentage over a longer 
period of time (14 days).21 Both FiberSense and the second-generation FAS are 
transdermal CGM devices which have the possible disadvantage of irritation at the implant 
site due to continuous movement of the transdermal optical fiber. The PreciSense A/S 
device proposed by Nielsen et al. and recently acquired by Medtronic has the potential to 
overcome this disadvantage due to it being a fully implanted degradable microsensor. In 
a preclinical in vivo study, this microsensor displayed in a MARD of 11.4% over a period 
of 70 hours.22 All three devices can be categorized as fluorescent affinity sensors and are 
based on a competitive binding assay. 
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Modified Con A and thiolated β-cyclodextrins (β-SH-CDs) 
Quantum dots (QDs) have been used to create glucose sensors. QDs have unique 
optical properties such as minimal photobleaching, narrow emission band, and broad 
excitation band that make them good candidates to be used as sensor components. A 
FRET-based glucose sensor composed of Concanavalin A (ConA)-conjugated CdTe QDs 
and thiolated β-cyclodextrins (β-SH-CDs)-modified AuNPs was investigated.23 Briefly, 
when the glucose concentration is low, β-CDs attach to the receptor protein ConA and the 
fluorescence caused by the QDs is quenched by the gold nanoparticles (AuNPs); however, 
as the glucose concentration increases, glucose molecules displace β-CDs and bind to 
ConA, thus allowing the fluorescence emitted by the QDs to be detected.  
The advantages of this approach are its sensitivity and selectivity. However, the 
toxicity of QDs and the low working range of this sensor hinder its advancement for in 
vivo use.  
 
Con A and Glycodendrimer 
Recently, an alternative approach to the Con A/dextran assays was proposed. This 
new method utilizes polyamidoamine (PAMAM) dendrimers as the competing ligand 
instead of dextran. Results showed the detection of glucose (0 to 300 mg/dL) within 5 
minutes.24 Like dextran, dendrimer is a multivalent glycoconjugate and therefore have 
multiple binding sites for ConA molecules to interact with. However, dendrimer has more 
available mannose residues than dextran, thus increasing its binding affinity to ConA an 
improving its sensitivity in detecting glucose.25 However, more recent work published by 
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Cummins in 2013, suggested that although these multivalent assays result in higher 
binding affinity, one main challenge is the lifespan and reversibility over longer periods 
of time due to these aggregates.  The results suggested that assays with multivalent 
competing ligands had high sensitivity initially but over time the fluorescence intensity 
became unstable as a result of long term aggregation.26 Therefore, in 2014, Cummins et 
al introduced a new competing ligand, mannotetraose, that is based on monovalent binding 
with ConA to overcome aggregation and reversibility issues without affecting the high 
binding affinity required to be sensitive to changes in physiological glucose 
concentration.27  
 
Current Work on ConA/Mannotetraose Based Glucose Sensing Assay 
Recently, mannotetraose was introduced as a potential alternative competing 
ligand with improved sensitivity and reversibility due to its non-aggregative nature when 
bound to ConA. Mannotetraose consist of three mannose residues that can fully bind to 
an individual binding site on ConA.28 The nature of its binding produces the high 
binding affinity that is required for glucose sensing, when bound to ConA without the 
production of aggregates.  
Herein, this work explored the development of a FRET assay based on this 
ConA/Mannotetraose pair. It examined its binding affinity under FRET conditions, and 
its FRET efficiency and sensitivity to changes in physiologically relevant glucose 
concentration compared to traditionally used competing ligand, dextran. Finally, this 
work aimed to encapsulate this assay within a thermo-responsive biocompatible 
11 
membrane and it evaluated the assay’s glucose sensing capabilities from within the 
membrane. 
12 
CHAPTER II  
PEGYLATION OF CONA TO IMPROVE THERMAL STABILITY* 
Introduction 
ConA, a lectin extracted from the jack bean, is a tetramer at physiological pH (7.4) 
comprised of four identical monomeric subunits (MW~25 kDa).29, 30 Each monomer 
contains an independent carbohydrate binding site, for which glucose and mannose 
monosaccharide can bind.16 It has been shown that ConA has the ability to reversibly bind 
to glucose with an affinity of ~400 M-1.31 This affinity allows the capability for ConA to 
track physiologically relevant glucose concentrations. Therefore, ConA is an attractive 
receptor to be used in a next generation non-enzymatic based glucose sensor. 
The first noted ConA-based competitive binding assay for glucose sensing was 
developed by Schultz et al. and employed 70 kDa fluorescein-isothiocyanate dextran 
(FITC-dextran) as the competing ligand.32 This scheme used a semi-permeable membrane 
to contain the sensing assay and allowed glucose to equilibrate with the device’s external 
environment.  Changing glucose concentrations within the membrane changed the 
equilibrium binding of assay components, which was transduced into a fluorescent signal 
that could be measured. Since this introduction, many different variations of the sensing 
assay have been designed and studied using the same scheme due to its tremendous 
potential for use in CGM devices.33-38 Certain assay variations have immobilized ConA to 
* Part of this chapter is reprinted with permission from A.K. Locke, B. M. Cummins, A. A. Abraham and 
G. L. Coté. “ PEGylation of Concanavalin A to Improve Its Stability for an In Vivo Glucose Sensing 
Assay,” Analytical Chemistry 2014, 85(11), 5397-5404. Copyright 2014 American Chemical Society. 
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a solid-phase (microdialysis membranes, beads, etc.) while leaving the competing ligand 
in free solution.39 This approach has been shown to track glucose concentrations in the 
body for up to 16 days.20 Other variations have left both assay components in free solution.  
Practically, this approach allows the sensor to be developed modularly, where the assay 
can be developed without requiring the semi-permeable membrane. In addition, this 
approach can potentially minimize the equilibration time to changes glucose 
concentrations. However, the solution based approach has shown problems with stability 
which is a major obstacle in the advancement of the technology.26 
  This instability has partly been due to the specific sugar-dependent, aggregation 
seen in assays that pair traditional high-affinity competing ligands (e.g. dextran, 
glycosylated dendrimer, etc.) with ConA in free solution.40, 41 Since ConA is a tetramer, it 
presents multiple binding sites that can aggregate with these multivalent competing 
ligands over time. The resulting lattice-type aggregate eventually precipitates out of 
solution and requires a significantly high concentration of glucose to break it apart. This 
type of instability has recently been addressed by the introduction of a new type of 
fluorescent competing ligand. This ligand avoids this specific aggregation by presenting a 
single high affinity moiety for ConA to bind. As a result, the ligand does not present 
additional residues for ConA to bind once it is already bound, allowing for the assay to 
remain stable in free solution.  
Another aspect of the original assay’s instability is associated with ConA’s thermal 
denaturation at physiological temperatures.  Since ConA is a protein, it is prone to un-
folding, aggregation, and degradation.42, 43 At elevated temperatures, the associated energy 
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can increase the likelihood that the protein unfolds. This unfolding can expose the 
hydrophobic residues, typically found in the interior of the protein, to the solvent. These 
residues can then interact with neighboring exposed hydrophobic groups leading to 
aggregation. This aggregation is believed to be irreversible and diminishes the solubility 
and activity of the protein.34, 44 Vetri et al. have reported that ConA undergoes this 
denaturation-induced aggregation at ~40 oC.45 Changes in ConA’s activity due to 
aggregation can significantly impact the glucose response of the assay by changing the 
concentration of active binding sites for which glucose can bind. Therefore, to maximize 
the in vivo lifetime of a ConA-based glucose assay, it is desirable to minimize the rate of 
ConA’s thermal denaturation at physiologically relevant temperatures. The 
immobilization of ConA to the solid-phase presumably maintains the assay’s stability by 
either stabilizing ConA and/or preventing unfolded ConA from aggregating with itself.   
In addition to this thermal denaturation, ConA has a tendency to adhere to 
positively charged surfaces. This electrostatic interaction is due to ConA’s overall 
negative charge under physiological conditions with isoelectric point (pI), defined as the 
pH at which a particular molecule carries no net electrical charge, for ConA is a pI~5.46 
This adhesion of ConA to surfaces or molecules can change the concentration and the 
activity of the receptor in solution. This becomes important when considering 
encapsulation of the assay for the purpose of in vivo implantation. Layer-by-layer (LbL) 
microcapsules are attractive semi-permeable candidates that can be tuned to effectively 
encapsulate the assay while allowing for the rapid equilibration of smaller analytes with 
its exterior environment (e.g. glucose). However, proteins have shown the tendency to 
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electrostatically attach to the capsule’s inner charged surface.47 If ConA behaves in a 
similar manner, the functionality of the assays would be affected as the availability of 
active receptors within the capsules may decrease. Thus, if LbL micro-capsules are to be 
used, it would be preferable for ConA to avoid undergoing electrostatic interactions with 
the capsule.48 
PEGylation is the process by which PEG chains are covalently attached to various 
molecules and surfaces to improve their stability, solubility, and biocompatibility.49, 50 The 
enhanced stability and solubility of a molecule (e.g. protein) via PEG chains is believed 
to be a result of a hydration barrier created by the grafted hydrophilic chains.51 In addition, 
the rapid mobility of the chains provides a steric hindrance effect that may aid in the 
reduction of particle-particle interaction depending on the chain length.52 These 
characteristics of PEG are believed to aid in the reduction of protein aggregation and 
precipitation. Groups such as Rajan et al., Rodriguez-Martinez et al. and Veronese et al. 
have shown evidence of this with the attachment of different molecular weight PEG chains 
to protein molecules such as α-chymotrypsin and a hematopoietic cytokines.53-55 
Furthermore, Wu et al. have showed an additional advantage of the chains in the role of 
masking surface charges to minimize non-specific electrostatic binding of proteins or cells 
to their imaging contrast agent.56 
These characteristics have allowed for PEGylation to be used to improve drug 
delivery systems, reduce protein adhesion, and increase molecular solubility in free 
solution. In terms of ConA, Kim and Park have shown that the conjugation of PEG chains 
to ConA increased its solubility at room temperature (22 oC) for the purpose of designing 
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a hydrogel comprised of immobilized ConA for insulin delivery.57, 58 Herein, we 
investigate the use of PEGylation to minimize the aforementioned non-specific 
interactions of ConA to improve the associated stability of the solution-based glucose 
monitoring approach in a physiologically relevant environment. We show that PEGylation 
decreases the rate of ConA aggregation with itself at body temperature without 
significantly affecting the binding affinity to the fluorescent competing ligand and its 
ability to track physiological glucose concentrations. We also observe that PEGylation 
reduces the electrostatic interactions between the lectin and positively charged surfaces 
which may prove to be useful for microencapsulation of the assay for in vivo glucose 
sensing. 
 
PEGylation of ConA and Characterization 
ConA was PEGylated with 5 kDa mPEG-NHS (SC), a primary amine reactive 
polymer that contains a succinimidyl carbonate linker. Briefly, ConA was dissolved in 
sodium bicarbonate buffer (10 mg/mL). The solution’s peak absorbance at ~280 nm was 
measured using a Hitachi U-4100 UV-Vis-NIR spectrophotometer (Hitachi High 
Technologies American Inc., U.S.) to determine the concentration of the solution using 
an extinction coefficient of 118,560 M-1cm-1 based on the E1% of 11.4 and MW of ~104 
kDa.59 A highly-concentrated aliquot of MaM was added to the ConA solution for a final 
MaM concentration of 1.9 mg/mL in an attempt to protect the activity of the binding 
sites of ConA during the reaction. Next, mPEG-NHS (SC) was added at a molar ratio of 
16:1 to the ConA monomer. At 22 oC, this solution was mixed on a rotating wheel for 6 
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h and then allowed to continue reacting for an additional 18 h without mixing. The 
solution was subsequently separated into two dialysis tubes (MWCO 20 kDa). The first 
tube was dialyzed against sodium bicarbonate buffer for PEGylation characterization 
with fluorescamine, while the other was dialyzed against TRIS buffer for all other 
experiments. Following dialysis, absorption measurements were again performed to 
determine the final PEGylated ConA concentrations, using the same molar extinction 
coefficient as unmodified ConA. 
The average degree of PEGylation was estimated using fluorescamine, as it is a 
useful tool to track the concentration of primary amines within a solution.60 
Fluorescamine becomes fluorescent after reacting with primary amines, and changes in 
fluorescence intensity can be descriptive of the makeup of the solution. This was used to 
compare identical concentrations of unmodified and PEGylated ConA to determine their 
relative concentrations of primary amines. This difference is related to the approximate 
number of mPEG chains grafted per ConA monomer.   
Briefly, a range of concentrations of unmodified ConA and PEGylated ConA (0 
to 2.5 μM) were prepared in sodium bicarbonate buffer (1.5 mL). Then, 500 μL of 
fluorescamine (0.3 mg/mL in acetone) was added to each solution and mixed well. 
Subsequently, 100 μL of each solution was added to a standard black 96-well 
microplate. After 5 minutes, the fluorescence intensity of each solution was measured 
using a TECAN Infinite 200 PRO microplate reader (Tecan Group Ltd, Männedorf, 
Switzerland) at  ⋋ex = 390 nm and ⋋em = 475 nm. These fluorescence intensities were 
plotted against the corresponding ConA concentrations, and the linear regression was 
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performed to obtain the slopes, mmPEGConA and mConA. These slopes were used in Equation 
1 to estimate the average degree of PEGylation (DP), similar to Wen et al.61 
𝐷𝑃 = (1 −
𝑚𝑚𝑃𝐸𝐺𝐶𝑜𝑛𝐴
𝑚𝐶𝑜𝑛𝐴
) ∗ 13 
Equation 1. 
 
                                              
This equation was utilized under the assumptions that fluorescamine could 
originally interact with each of the primary amines on unmodified ConA and that it 
could interact with each of the primary amines that remained on PEGylated ConA.  
Therefore, the differences in the fluorescence intensities are assumed to be solely due to 
the decrease in the primary amine concentration resulting from the conjugated PEG 
chains. 
 
 
Figure 1. Fluorescence intensity of fluorescamine in the presence of PEGylated and 
native ConA to determine the degree of PEGlyation. 
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Each ConA monomer contains thirteen primary amines that can potentially be 
PEGylated (12 lysine residues and the N–terminus).58 Figure 1 shows that 
fluorescamine’s fluorescence intensity was consistently lower in solutions of PEGylated 
ConA than it was for unmodified ConA at the same concentration. This indicates that the 
presence of the mPEG chains decreased the interaction between fluorescamine and the 
primary amines on the PEGylated ConA. Equation 1 estimates an average of ~5 mPEG 
chains grafted per ConA monomer. Assuming a Poisson distribution, this degree of 
PEGylation would mean that 99.9% of ConA tetramers have 8 or more mPEG chains per 
tetramer.  While the average number of mPEG chains grafted per ConA could be lower 
than the estimated value from Equation 1, the PEGylated ConA is expected to be 
sufficiently modified for the purpose of this study. 
 
Aggregation Study via Dynamic Light Scattering Study to Determine Thermal 
Stability 
 The thermal denaturation of unmodified and PEGylated ConA in free solution 
was tracked by monitoring the aggregation in a physiologically relevant buffer with 
dynamic light scattering (DLS).  In sealed disposable polystyrene cuvettes (1 cm path-
length), solutions of unmodified and PEGylated ConA (10 μM each) were prepared in 
triplicate in TRIS buffer. The cuvettes were incubated at 37 oC. Over the course of 30 
days, measurements were taken at seven different time points (Day: 0, 1, 2, 4, 9, 16, and 
30) with re-suspension of the particles via aspiration before each measurement. A 
Malvern Nano Zetasizer (Malvern Instruments Ltd., Worcestershire, UK) was used to 
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measure the average particle diameter (Z-average) as well as the poly-dispersity index 
(PDI) of the particles within each solution. 
Per Figure 2, the average particle size in the unmodified ConA solution displayed 
an initial (i.e. Day 0) diameter of 8 + 0.03 nm, consistent with previous reports for the 
hydrodynamic diameter of unmodified tetrameric ConA.62 The average particle size in 
the PEGylated ConA solution displayed a higher initial diameter of 30 + 0.22 nm (Figure 
2), due to the increase in the aforementioned hydration barrier associated with multiple 
mPEG chains.   
 
 
Figure 2. The Z-average particle size of native, unmodified ConA versus PEGylated 
ConA to determine how each respond to temperature at 37 oC over the course of 30 days. 
 
After 24 hours, the average diameter of particles in the unmodified ConA 
solution increased to over 400 nm. After 30 day at 37 oC, the average diameter of 
particles in the solution of unmodified ConA increased to ~1.8 μm (Figure 2), indicating 
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aggregation of the ConA molecules. The slight decrease in particle size for unmodified 
ConA be-tween Day 16 and Day 30 is believed to be due to the precipitation of the 
larger aggregates during the measurements. Overall, this type of aggregation clearly 
indicates that unmodified ConA is thermally unstable in this environment.  
In contrast, Figure 2 shows that the average particle size in the PEGylated ConA 
solution remained relatively constant at ~30-38 nm over 30 days at 37 oC. This indicates 
that PEGylated ConA displays negligible thermally-induced aggregation and suggests 
that ConA’s thermal stability has indeed been improved via this degree of PEGylation.  
The slight increase in standard error of the average size of PEGylated ConA could be 
due to the small percentage of ConA molecules that displays either low levels of 
PEGylation or no PEGylation at all.  Without sufficient PEGylation this population is 
expected to display properties similar to that of unmodified ConA. Strategies could 
potentially be employed to remove this small percentage prior to the use of PEGylated 
ConA in a sensor.   
The poly-dispersity of the particle sizes within a solution can also be used to 
describe that solution.  For instance, aggregation is expected to produce a large 
distribution of particle sizes, which would display a high level of poly-dispersity.  For 
the DLS measurements reported here, the poly-dispersity index (PDI) indicates the level 
of poly-dispersity and ranges from 0 (low dispersity) to 1 (completely disperse).    
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Figure 3. The average PDI of native, unmodified ConA compared to PEGylated ConA 
after exposure to 37 oC for 30 days. 
 
Figure 3 shows the comparison of time-dependent PDI of the solutions for 
unmodified and PEGylated ConA at 37 oC. Initially, the PDI of the PEGylated ConA is 
slightly higher than the unmodified ConA.  This is presumably due to the range of 
degrees of PEGylation that is to be expected with a Poisson distribution.  However, over 
the course of the 30 days, of this experiment, the PDI of the unmodified ConA solution 
increased from 0.2 to 0.87 implying that the solutions of unmodified ConA became 
increasingly heterogeneous as the formation of aggregates increased (Figure 3). In 
comparison, Figure 3 shows that PEGylated ConA remained relatively homogeneous in 
solution over the same time period. This result confirms what was observed in Figure 2; 
the average particle size of PEGylated ConA remains relatively constant and does not 
aggregate. These characteristics suggest that this degree of PEGylation improves the 
stability of ConA at physiological conditions. It is important to note that this improved 
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stability could be due to an inhibition of the aggregation of unfolded ConA via steric 
hindrance, an improved conformational stability of ConA, or a combination thereof.   
 
Binding Affinity Study Using Fluorescence Anisotropy 
The binding affinity of unmodified and PEGylated ConA to the rationally-
designed fluorescent competing ligand, APTS-MT, was evaluated using fluorescence 
anisotropy.  In the wells of a standard black 96-well microplate, solutions were prepared 
with a fixed concentration of APTS-MT (100 nM) and a range of concentrations of 
either unmodified or PEGylated ConA (4 nM to 10 μM).  Solutions were prepared in 
TRIS buffer, and each well had a final volume of 100 μL.  The appropriate controls 
(TRIS buffer & 100 nM APTS-MT) were also added to separate micro-plate wells for 
baseline correction purposes. Time was then given for all solutions to reach equilibrium 
(~10 min) at 22 oC, and a TECAN Infinite F200 microplate reader fitted with polarizers 
was used to measure the steady-state fluorescence anisotropy of each solution (⋋ex = 483 
nm; ⋋em = 540 nm). The affinity was determined by plotting the average anisotropy as 
function of the tetrameric ConA concentration on a logarithmic scale and fitting the data 
with a Boltzmann curve.  
To determine the stability of this binding in a physiologically relevant 
environment, the stock solution of PEGylated ConA was then stored at 37 oC for 30 
days. Portions of this stock solution were withdrawn at various time points during this 
period (Days: 1, 2, 4, 9, 16, and 30) and tested via fluorescence anisotropy in the same 
manner. 
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While PEGylation does increase the stability of ConA, the PEGylated protein 
must maintain its binding capability to be functional in a competitive binding assay.  The 
degree to which ConA’s binding is affected by PEGylation is likely to be dependent on 
the chain length and the number of chains grafted.  However, for a given degree of 
PEGylation, it is expected to have a greater effect on the binding of the competing ligand 
than that of glucose due to relative size. Therefore, ConA’s binding to the fluorescent 
competing ligand (APTS-MT) of the competitive binding assay was investigated.  For 
PEGylated ConA to be used in a competitive binding assay and optimally track 
physiological glucose concentrations, an affinity of 105 to 107 M-1 to the competing 
ligand is required.28 Similar binding studies would need to be performed if a different 
competing ligand or degree of PEGylation were to be used.  If this competing ligand was 
a traditional competing ligand, additional experiments should be performed to determine 
whether sugar-dependent aggregation is occurring. It is possible that the PEGylation of 
ConA could avoid the aggregation with such ligands through steric hindrance effects.   
Herein, the binding affinity (Ka) of APTS-MT to unmodified and PEGylated ConA was 
evaluated using fluorescence anisotropy. Fluorescence anisotropy is a useful tool that 
can provide information about protein-ligand interactions. Briefly, polarized light is used 
to selectively excite a portion of the fluorescent ligand within solution. The average 
rotational diffusion of the molecules at equilibrium can be tracked with the polarization 
of the fluorescence. This fluorescence polarization/anisotropy increases as the binding of 
the fluorescent ligand to the desired protein increases.63 The parallel and perpendicular 
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components of the fluorescent emission can be measured, and the fluorescence 
anisotropy can be calculated with Equation 2.64 
                                          
𝑟 =
𝐼𝑣𝑣 − (𝐼𝑣ℎ ∗ 𝐺)
𝐼𝑣𝑣 + (2 ∗ 𝐼𝑣ℎ ∗ 𝐺)
 
Equation 2.  
                                                             
In this equation, r is the anisotropy, G is the correction factor due to the 
instrument’s sensitivity or biased to one polarizer over the other, and Ivv and Ivh are the 
vertically and horizontally polarized fluorescence intensities, respectively. The 
dissociation constant (Kd) was determined from a plot of the anisotropy as a function of 
varying mPEG-ConA (log10 [mPEG-ConA ConA]) concentration using a Boltzmann 
curve fit (Equation 3). 
 
𝑟 = 𝐹0 +
(𝐹∞ − 𝐹0)
1 + exp (
𝐾𝑑 − 𝑥
𝑠𝑙𝑜𝑝𝑒 )
 
Equation 3. 
 
  The association constants (Ka) for unmodified and PEGylated ConA were ~5.7 + 
0.37 x 106 M-1 and ~5.4 + 0.37 x 106 M-1, respectively. Therefore, PEGylation did not 
significantly affect the binding affinity of ConA to the competing ligand. Moreover, 
PEGylated ConA’s affinity falls within the range necessary for this assay to be 
optimized across physiological glucose concentrations.  
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In addition, the capability of PEGylated ConA to maintain its binding affinity 
after incubation at 37 oC was evaluated. Since anisotropy is sensitive to scatter, 
measurements of unmodified ConA were not possible due to the large aggregate 
formation similar to those observed during the thermal studies.  
 
 
Figure 4. Binding affinity of PEGylated ConA to the competing ligand demonstrating its 
stability over 30 days. 
 
Figure 4 indicates that the binding affinity of PEGylated ConA to the competing 
ligand remained stable at ~5.4 + 0.5 x 106 M-1 over 30 days. The slight fluctuations in 
affinity may be related to pipette error during mixing and sample transfer from the 
cuvette to the microplate. This result, along with its thermal stability in free solution, 
suggests that the activity of ConA can be maintained via PEGylation which may allow 
for long term functionality of a ConA-based sensor. Furthermore, because ConA’s 
binding is due to its folded structure, the long term binding stability suggests that the 
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protein maintains its functional conformation over time. Therefore, we expect that 
PEGylation is most likely enhancing ConA’s conformational stability in addition to any 
steric-hindrance effects that it also imparts. 
  
Non-Specific Adsorption Study 
Light scatter can be used to investigate the interaction of macromolecules in free 
solution, including those containing proteins. For example, Park et al. have used this 
method to study the electrostatic interaction between different biological proteins (i.e. 
BSA, RNase and lyzozymes) and poly-electrolytes (i.e. PSS, PVS, etc.) via turbidity 
measurements at 420 nm.65 This turbidity is related to the amount of aggregation within 
the various samples and is indicative of the specific and/or nonspecific binding between 
molecules. 
In a similar manner, the electrostatic interactions of PAH+ (a common 
polyelectrolyte used in LbL) with un-modified and PEGylated ConA was measured in 
this study. ConA absorbs ultraviolet light with a peak at ~280 nm, and absorbs a 
negligible amount of light above ~320 nm. Therefore, any extinction of the incident light 
higher than 320 nm is assumed to be scattered light that is associated with aggregate 
formation within the solution.  
 In separate centrifuge tubes, each of the following solutions was prepared in 
triplicate in TRIS buffer at 22 oC: PAH+ with ConA, PAH+ with PEGylated ConA, 
ConA, PEGylated ConA, and PAH+.  Each individual component in each solution was 
prepared at 10 μM for comparison. Immediately after preparation, 100 μL of each 
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sample was extracted and added to a standard UV-Vis 96-well microplate. The turbidity 
of each solution was then measured at 400 nm using a TECAN Infinite 200 PRO® 
microplate reader. These measurements were also performed at 30 min, 1 h, 24 h, and 48 
h. 
 
 
Figure 5. Scattering effect due to electrostatic interaction between native, unmodified 
ConA (left) and PEGylated ConA (right) with PAH+. 
 
The electrostatic-induced aggregation between the negatively charged 
unmodified ConA and the positively charged PAH+ is observed with the increase in 
scatter in comparison to its control, unmodified ConA without PAH+ (Figure 6). 
Moreover, the unmodified ConA/PAH+ aggregates were observed as white particulates 
within the solution (Figure 7). In contrast, PEGylated ConA’s interaction with PAH+ 
showed relatively no change in scattering, indicating no aggregate formation. This may 
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be due to the masking of the charges on ConA by the mPEG chains, and thereby 
preventing ConA adhesion to PAH+. To validate this data, separate solutions of ConA, 
PEGylated ConA, and PAH+ were used as controls. During the same time period there 
were no changes in scatter of these controls. This establishes that the increase in scatter 
was a direct result of the interaction between unmodified ConA and PAH+. Therefore, 
PEGylation proved useful in the minimization of electrostatic-induced aggregation of 
ConA. This is desirable when aiming to encapsulate the ConA based assay within a 
carrier (e.g. layer-by-layer microcapsules) as it may allow the assay to remain free in 
solution and thus, maintain its full activity. 
 
 
Figure 6. Aggregate formation (‘white particulates’) during native, unmodified 
ConA/PAH+ interaction (left) compared to PEGylated ConA/PAH+ interaction (right). 
  
Glucose Response Study 
PEGylated ConA was tested using a fluorescence anisotropy assay comprised of 
200 nM APTS-MT (the competing ligand) and 1 μM PEGylated ConA to determine its 
effectiveness in tracking physiological glucose concentrations. Various concentrations of 
D-glucose (0 to ~800 mg/dL) were prepared in TRIS buffer and verified using an YSI 
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2300 Stat Plus biochemistry analyzer. A stock assay containing 2 μM mPEG-ConA and 
400 nM APTS-MT was prepared in TRIS buffer.  In a standard black 96-well 
microplate, 50 μL of the assay and 50 μL of the appropriate glucose concentrations were 
added to separate wells and mixed well.  This created wells containing a final assay 
concentration of 200 nM APTS-MT and 1 μM PEGylated ConA with glucose 
concentrations ranging from 0 to ~400 mg/dL. Like before, the appropriate controls 
(TRIS buffer & 200 nM APTS-MT) were also added to separate micro-plate wells for 
baseline correction purposes. After time was given for the solutions to equilibrate (~10 
min) at 22 oC, the steady-state anisotropy of each solution was measured with the 
TECAN Infinite F200 microplate reader. 
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Figure 7. Glucose response of fluorescence anisotropy based assay using PEGylated 
ConA. The data was fitted to a standard competitive binding equation (solid line). 
 
PEGylated ConA was expected to maintain its response to glucose because the 
binding of APTS-MT was not hindered by the presence of the PEG chains (Figure 4) and 
glucose (MW ~180 Da) is smaller than APTS-MT (MW ~1 kDa). To verify this, 
fluorescence anisotropy was used to track the behavior of an assay comprised of 
PEGylated ConA and APTS-MT in the presence of varying concentrations of glucose 
(Figure 7). This displays a characteristic competitive binding curve, where the 
anisotropy decreases in response to increasing glucose concentrations. This indicates that 
the PEGylation of ConA does not inhibit its ability to track physiological glucose 
concentrations in the competitive binding assay. 
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CHAPTER III 
CHARACTERIZATION OF PEGYLATED CONA-MANNOTETRAOSE BASED 
ASSAY USING FRET AND COMPARISON OF EFFICIENY TO 
TRADITIONAL COMPETING LIGAND DEXTRAN* 
Introduction 
Herein, the PEGylated ConA and APTS-MT based assay is modified into a 
FRET based assay in order to develop a glucose sensing assay that can be implanted in 
vivo. The competing ligand, mannoteraose, is rationally-designed to present a single 
binding epitope (core trimannose) in close proximity to the signaling fluorophore, APTS. 
Using traditional, multivalent ligands for comparison (two different sized dextrans), we 
show that this new type of ligand improves the FRET efficiency upon binding to 
acceptor-labeled lectin. We then display that this enabling advantage improves the 
sensitivity of the assay to changes in physiological glucose concentrations (0 to 400 
mg/dL) in comparison to the dextrans. Finally, we show that this new ConA-
Mannotetraose based assay is thermally stable after incubation at body temperature (37 
oC) for 30 days with a MARD of less than 10%. 
FRET is a phenomenon where the energy of an excited fluorophore can non-
radiatively transfer its energy to another fluorophore. With the properly chosen donor 
* Part of this chapter is reprinted with permission from A.K. Locke, B. M. Cummins, and G. L. Coté. 
“High Affinity Mannotetraose as an Alternative to Dextran in ConA Based Fluorescent Affinity Glucose 
Assay Due to Improved FRET Efficiency,” ACS Sensors 2016, 1 (5), 584-590. Copyright 2016 American 
Chemical Society. 
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and acceptor fluorophores (overlapping emission/excitation spectra), the donor transfers 
its energy when the acceptor fluorophore is brought in close proximity (Equation 3). In 
this equation, E is the FRET efficiency, and R and Ro are the distance between the two 
fluorophores and the Forster radius, respectively.66 
 
𝐸 =
1
1 + (
𝑅
𝑅𝑜)
6 
Equation 4. 
 
Labelling the competing ligand, mannotetraose, with the donor fluorophore 
(APTS) and the receptor, ConA with an acceptor fluorophore (TRITC), the assay is 
designed to induce FRET when complexes are formed. The equilibrium of these 
complexes shifts accordingly to changes in glucose concentration, and this shift can be 
tracked by measuring the ratio of the peak fluorescence intensities of the two 
fluorophores. 
 
Determining the Binding Affinity of ConA Based Assay Using FRET 
The binding affinity of the three different competing ligands to mPEG-TRITC-
ConA was determined by tracking the fluorescence emission spectra during independent 
titration studies. First the competing ligands were synthesized as follows: 
The synthesis of APTS-MT was performed using reductive amination and was 
previously discussed in detail.28 Briefly, 13.5µL of 1 M APTS in acetic acid was added 
to ~1 mg of mannotetraose, allowing for the Schiff base intermediate to form between 
  
34 
 
the reducing terminus of mannotetraose and APTS. To stabilize this into a covalent 
bond, 13.5µL of 1 M sodium cyanoborohydride in tetrahydrofuran was added to the 
acetic acid mixture. This was well mixed and allowed to react at room temperature for 
15 hr.  The APTS-MT product was then purified via a HILIC column. 
Two unique dextrans (MW: 70 kDa and 2 MDa) were labeled with APTS using 
the same reductive amination approach. Dex-2M allows for comparison with the 
proposed competing ligand due to similar binding affinities while Dex-70k is the most 
common competing ligand used in ConA based affinity assays. These fluorescent 
ligands (APTS-Dex-70k and APTS-Dex-2M) were synthesized using an APTS labeling 
kit from Prozyme®. Briefly, stock solutions of 50 mg/mL Dex-70k and 100 mg/mL 
Dex-2M were prepared in DI H2O. Next, 10 µL and 20 µL of these solutions (Dex-70k 
and Dex-2M, respectively) were added to new centrifuge tubes. These solutions were 
centrifuged and then dried under a vacuum in a desiccator for 6 hours. Separately, the 
APTS reagent solution was then prepared by mixing the APTS solution (2.4 µL), APTS 
catalyst (6 µL) and reductant solution (2.4 µL) from the kit. Then, APTS reagent 
solution (4 µL) was added to each dried dextran samples and mixed well. These samples 
were sealed and placed in a water bath at 37 oC for 2 hours. After removing the solutions 
from the water bath, DI H2O (500 µL) was added to each solution. The samples were 
then purified via 10 kDa centrifugal filters (Nanocep® from Pall) before passing through 
a GE Healthcare illustra MicroSpinTM G-25 column at ~3000 rpm for 2 minutes. An 
absorbance scan, from 240 nm to 600 nm, of the purified solution was taken via a 
Tecan® microplate reader to determine whether the sugar was conjugated to the dye. 
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The estimated number of dyes per dextran was calculated using the sulfuric acid based 
method designed by Albalasmeh et al. (Figure 8).67 
 
Figure 8. Calibration curve of the absorbance of (1) Dex-2M and (2) Dex-70k in the 
presence of sulfuric acid. The curves were used to estimate the concentration of each 
dextran after conjugation of APTS dye. 
 
The synthesis of mPEG-TRITC-ConA has been previously described in detail. 
Briefly, 10 mg of TRITC-ConA was dissolved in ~1 mL sodium bicarbonate buffer. To 
occupy ConA’s binding site, 2 mg of MaM was added to the protein solution. Next, ~25 
mg of mPEG-NHS (5 kDa) was added to the solution for a molar concentration ratio of 
16:1 mPEG to ConA. The solution was then continuously mixed for 6 hours. 
Afterwards, the solution was allowed to incubate for another 18 hours at room 
temperature without mixing. Dialysis against TRIS buffer removed MaM and unbound 
mPEG-NHS. The final concentration of mPEG-TRITC-ConA was determined by taking 
an absorbance scan from 240 nm to 640 nm using UV-Vis spectrometer. 
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Next, stock solutions of mPEG-TRITC-ConA (15.4 µM) and APTS-MT (10 µM) 
were first prepared separately in TRIS buffer. In a 1 cm path-length cuvette (C1), 1 mL 
of the assay (3 µM mPEG-TRITC-ConA and 200 nM APTS-MT) was prepared in TRIS 
buffer from the stock solutions. Fluorescence emission (475 nm to 650 nm) was 
measured with an ISS PC1 spectrofluorometer (λex 450 nm). Subsequent emission scans 
were performed with the APTS-MT at the same concentration and decreased 
concentrations of mPEG-TRITC-ConA. Briefly, this was done by removing 500 µL of 
assay solution from C1 and adding 500 µL of 200 nM APTS-MT in TRIS buffer. This 
provided a new assay that comprised 200 nM APTS-MT and 1.5 µM mPEG-TRITC-
ConA. The solution was mixed thoroughly and allowed to re-equilibrate before 
measuring the fluorescence spectra. This method was repeated to achieve final 
concentrations of mPEG-TRITC-ConA of:  750 nM, 375 nM, and 187.5 nM. Separate 
fluorescent scans of 1 mL APTS-MT (200 nM) and 1 mL mPEG-TRITC-ConA (3 µM) 
in TRIS buffer were taken under the same excitation conditions as the controls.  
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Figure 9. Titration curves comparing the change in fluorescence intensity of the 
different donor conjugated ligands: (A) APTS-MT, (B) APTS-Dex-70k and (C) APTS-
Dex-2M; in response to in-creasing concentration of mPEG-TRITC-ConA (legend). All 
curves were normalized to the donor peak at 520 nm. 
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After all spectra were obtained from a given titration study (Figure 9), the 
fluorescence intensity at the peak emission for the donor fluorophore (i.e. APTS @ 520 
nm) was plotted against mPEG-TRITC-ConA concentration. Each curve was then 
normalized to 1 at ConA=0 nM and fitted with Equation 4, giving the association 
constant to ConA (Ka = 1/Kd) for the given competing ligand (Figure 10). This fit also 
generated F∞, which is related to the efficiency of FRET transfer when the given 
competing ligand is bound to ConA. 
 
𝐹[𝐶𝑜𝑛𝐴] =
1 − 𝐹∞
1 +
[𝐶𝑜𝑛𝐴]
𝐾𝑑
+ 𝐹∞ 
Equation 5. 
 
  This method was repeated to determine the binding affinity of APTS-Dex-2M 
(52 nM) to mPEG-TRITC-ConA (0 to 850 µM). An attempt was made to perform this 
for APTS-Dex-70k however, the results were inconclusive. This is because it’s affinity 
to ConA is too low to see an appreciable change in the donor fluorescence at these ConA 
concentrations. 
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Figure 10. Normalized peak fluorescence intensity of APTS-MT fitted to a Boltzmann 
curve to determine the binding affinity of the FRET based assay containing (A) APTS-
MT and (B) Dextran 2MDa as the competing ligand. 
 
First, to ensure that the binding affinities were still comparable even after 
PEGylation, the titration curves generated previously were used to determine the Ka. The 
plot of the fluorescence intensity, at the donor peak, against increasing concentration of 
mPEG-TRITC-ConA was fitted with Equation 4 and the binding affinity was determined 
to be 3.2 x 106 M-1 and 2.61 x 106 M-1 for APTS-MT and APTS-Dex-2M, respectively. 
Benzeval reported a similar binding affinity of ~1.42 x 106 M-1 for Dex-2M binding to 
ConA and our previous fluorescence anisotropy work reported an affinity of  
approximately 5 x 106 M-1 for PEGlyated ConA-APTS-MT assay which validates our 
findings.68 These Ka values are on the same order therefore we can assume that any 
difference in the fluorescence glucose response will be primarily due to the differences 
in the distance of the donor fluorophore (APTS) to the acceptor (TRITC) based on the 
structure and size of the competing ligands. 
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Comparing the FRET Efficiency of ConA Based Mannotetraose Assay Vs ConA 
Based Dextran Assay 
The approximate FRET efficiencies for the different competing ligands when 
bound to ConA were calculated using the parameter from the previous fit (F∞). Here, the 
value associated with the fluorescence of APTS-MT in the absence of ConA (100%) can 
be used as a control where there is no FRET transfer. The value associated with the 
fluorescence of APTS-MT in the presence of infinite ConA (F∞) indicates the percentage 
of the original fluorescence from APTS-MT when all APTS-MT molecules in solution 
are bound to ConA. Therefore, using Equation 6 the average FRET Efficiency (E) when 
bound to ConA can be calculated for each competing ligand. The average distance (r) 
between the APTS and the TRITC when the competing ligand is bound to ConA can be 
approximated using Equation 7 and the calculated efficiencies and the approximate 
Forster Radius (R0).
66 
 
𝐸 = 1 − 𝐹∞ 
Equation 6. 
 
𝑟 = 𝑅𝑜 (
1
𝐸
− 1)
1
6
 
Equation 7. 
 
           The eventual performance of the competitive binding assay is dependent on the 
efficiency of FRET (E) when the donor-labeled competing ligand is bounded with the 
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acceptor-labeled ConA. This efficiency was evaluated for each APTS-labeled competing 
ligand using the parameters from the titration binding study.  
APTS-MT is expected to have better FRET efficiency over the dextran based 
assays due to its size and the location of its single fluorophore on the competing ligand. 
The MW of mannotetraose is ~1 kDa compared to dextran (70 kDa and 2M Da). This 
much smaller size should ideally allow for its fluorophore to be brought closer in 
proximity to the fluorophores on ConA when bound compared to dextran.  
The titration plots in Figure 9 show a greater change in fluorescence intensity for 
the APTS-MT based assay compared to the APTS-Dex-2M based assay; over slightly 
similar concentration range. After normalizing the fluorescence intensity at 520 nm and 
fitting it to equation 4, APTS-MT had a much higher FRET efficiency of ~89% 
compared to that of APTS-Dex-2M whose efficiency was determined to be ~25%. 
Furthermore, when compared to the traditional Dex-70k, APTS-MT also displayed 
improved efficiency. Moreover, due to its lower affinity, APT-Dex-70k required a much 
higher concentration range of the fluorescently labeled receptor required to obtain a very 
small and inconsistent FRET change making it difficult to determine its exact FRET 
efficiency. 
The average distance between the two fluorophore in the absence of glucose was 
also calculated. FRET pair dyes APTS/TRITC have similar excitation and emission 
spectra to the commonly paired FITC/TRITC dyes. Therefore, their theoretical Forster 
Radius is expected to be similar and from the literature, FITC/TRITC is known to have 
an approximate Ro of 5 nm.69 This Ro value and the FRET efficiency calculated 
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previously was used to calculate the estimated average distance between the bound and 
unbound APTS/TRITC based assay via Equation 6 and Equation 7; which was 
determined to be 3.5 nm and 6 nm, respectively for APTS-MT and APTS-Dex-2M. 
 
Comparing the Glucose Response and Sensitivity of ConA Based 
Mannotetraose Assay Vs ConA Based Dextran Assay 
The glucose responses of the different individual assays were measured by 
tracking the change in fluorescence intensity of donor and acceptor fluorophore. Using 
the binding affinities estimated above, the concentration of mPEG-TRITC-ConA was 
optimized using Equation 8 to allow for at least 50% of the assay to be in its bound state 
prior to the introduction of glucose. 
 
% 𝐵 =
[𝐶𝑜𝑛𝐴]
𝐾𝑑 + [𝐶𝑜𝑛𝐴]
 
Equation 8. 
  
 A stock glucose concentration of 39,500 mg/dL was prepared in TRIS buffer. In 
a cuvette, 1 mL of the assay solution (200 nM APTS-MT and 1 µM mPEG-TRITC-
ConA) was prepared in TRIS buffer and mixed well. After giving sufficient time for the 
assay to reach equilibrium, the fluorescence emission was scanned (λex 450 nm, λex: 475-
675 nm). Aliquots of the stock glucose were added to the assay to vary the glucose 
concentration across physiological concentrations. After each addition, the solution was 
mixed well and given sufficient time to equilibrate prior to scanning the fluorescence 
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emission in the same manner. Fluorescence scans were recorded for glucose 
concentrations that ranged from 0 mg/dL to 400 mg/dL. This was done in triplicate for 
the APTS-MT assay and repeated for assays based on the APTS-Dex-2M ligand (52 nM 
APTS-Dex-2M and 3 µM mPEG-TRITC-ConA) as well as assays based on the APTS-
Dex-70k ligand (200 nM APTS-Dex-70k and 25 µM mPEG-TRITC-ConA) Higher 
concentrations of mPEG-TRITC-ConA were required in the APTS-Dex-70k assay 
because the affinity is lower for that competing ligand to bind to receptor. After the 
glucose-dependent fluorescence emission curves were obtained for each assay, the 
fluorescence intensity ratio (F520/F600) was calculated and plotted against the associated 
glucose concentration. The sensitivity of each assay was then calculated and compared. 
The data was then fitted to a Boltzmann curve to determine how well each assay can 
predict glucose concentration. 
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Figure 11. (A) The average glucose response of assays comprised 200 nM APTS-MT 
and 1 µM mPEG -TRITC-ConA showing improved FRET response and (B) 
predictability of glucose concentrations versus 52 nM APTS-Dex-2M and 1 µM mPEG-
TRITC-ConA. 
 
The performance of these two assays within the physiologically relevant glucose 
concentration range (0 to 400 mg/dL) was also evaluated in free solution at room 
temperature. (Figure 11). The results showed that the assay containing the fluorescently 
labeled monovalent ligand, APTS-MT, had a much greater FRET response to changes in 
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glucose concentrations. More importantly, APTS-MT was observed to be more accurate 
in predicting changes in glucose concentrations compared to APTS-Dex-2M. 
Furthermore, the average sensitivity of the assay to changes in glucose concentration 
was also calculated by determining the percent change in fluorescence ratio over the 
total glucose concentration range (%Δ F.ratio/mM). In free solution, the mannotetraose 
(1.3 + 0.7%) based assay is approximately four times more sensitive to changes in 
physiologically relevant glucose concentrations than APTS-Dex-2M (0.35 + 0.02%).  
Therefore, under the same conditions (i.e. same FRET pair fluorophores and 
temperature) the competing ligand mannotetraose appeared to have a better 
predictability and sensitivity to changes in glucose concentration than the dextran (2M). 
This may be due to the location of the fluorophore on these molecules. The size of 
mannotetraose allows the distance between its fluorophore and the fluorophore on the 
ConA to be in closer proximity than if the same fluorophore was on dextran; which 
contains multiple long branches terminated with the fluorophore. These multiple long 
branches therefore result in a less controlled placement of the fluorophore and in turn a 
less controlled distance between the donor and acceptor fluorophores compared to the 
mannotetraose based ligand. This in turn affects both the FRET efficiency and sensitivity 
of the assay resulting in the dextran based assay to be less efficient in predicting glucose 
concentrations.  
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Figure 12. (A) The average glucose response of assays comprised 200 nM APTS-MT 
and 1 µM mPEG -TRITC-ConA showing improved FRET response and (B) 
predictability of glucose concentrations versus 52 nM APTS-Dex-70k and 25 µM 
mPEG-TRITC-ConA. 
 The glucose response of APTS-MT based assay was also compared to that of an 
assay comprised dextran with a MW of 70 kDa (Figure 12). This dextran is the most 
common dextran reported in literature for use in ConA based glucose sensing assays.36 
In literature, its binding affinity to ConA is reported to be ~15,000 M-1.18 Several 
research groups have shown this dextran to function within a ConA based glucose sensor 
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with good response to changes in physiological glucose concentrations, both in vitro and 
in vivo, when a substantial amount of ConA or dextran is used.33 However, many have 
observed sensor failure over time with one possibility of the failure linked to aggregate 
formation between ConA and dextran. Therefore, previous work has shown that 
mannotetraose can act as a replacement for this competing ligand with improve 
functionality due to its non-aggregative behavior when interacting with ConA.28 
It was observed that unlike APTS-Dex-2M the concentration of mPEG-TRITC-
ConA had to be increase substantially in order to observe even the slightest change in 
FRET in response to glucose. This is due the Dex-70k’s low Ka in a ConA based assay. 
For a dextran 70k based assay, for at least 50% of its molecules to be in the bound state, 
~66 µM of ConA (note ConA solubility limit is 100 µM) is required compared to only 1 
µM for a ConA-mannotetraose assay. 
Herein, the mPEG-TRITC-ConA concentration which resulted in at least 25% of 
the molecules to initially be bound was used with hopes in minimizing aggregate 
formation between the two molecules which is also an issue with these ConA-Dextran 
based assays. It was observed that its change in fluorescence ratio is greater than dextran 
2M with an approximate sensitivity of 0.7 + 0.1% across the same physiological range. 
Chinnayelka et al. have also reported similar sensitivity of ~0.7% for a ConA-Dextran 
70k based FRET assay in free solution.70 However, when compared to APTS-MT, the 
mannotetraose based assay still had improved sensitivity and reproducibility (note the 
large error bars for APTS-Dex-70k assay) in response to changes in glucose 
concentration overall.  The concentration of the competing ligand could have also been 
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increased in these experiments. However, the ideal sensor should be sensitive to lower 
glucose concentrations, which requires very low concentration of the competing ligand. 
Glucose Response under Thermal Conditions 
The glucose response of an assay containing mannotetraose at 37 oC was 
evaluated after 30 days to determine the assay’s stability and activity under physiologic 
thermal conditions (Figure 13). Results show that the MARD% over the hypoglycemic 
range (< 70 mg/dL) was ~9%, the euglycemic range (i.e. between 70 and 180 mg/dL) 
was 2% and the hyperglycemic range (<180 mg/dL) was ~4%. The overall MARD 
between 0 and 400 mg/dL was ~5%. 
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Figure 13. (A) Normalized fluorescence ratio of assay composed of ConA-MT and (B) 
predicted versus actual glucose response of same assay indicating the assay’s ability to 
predict changes in glucose concentrations with a MARD of less than 10% after 30 days 
incubation at 37 oC. 
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CHAPTER IV 
ENCAPSULATION OF ASSAY WITHIN BIOCOMPATIBLE AMPS PNIPAAM 
HYDROGEL 
Introduction 
Previous chapters introduced a thermally stable, non-aggregative glucose sensing 
assay comprised mPEG-TRITC-ConA and APTS-MT. Thus far, this assay has only been 
evaluated in free solution. Therefore, within this chapter this assay is encapsulated 
within the biocompatible membrane AMPS-PNIPAAm, developed at Texas A&M 
University by Dr. Melissa Grunlan’s research group, and evaluated for its functionality 
as a glucose biosensor.  
PNIPAAm is a hydrogel that is synthesized via copolymerization of N-
isopropylacrylamide and a crosslinker N, N’-methylenebisacrylamide (BIS). In its 
traditional form, as a single network (SN) hydrogel, PNIPAAm is able to slowly switch 
between a swollen (hydrophilic) and deswollen (hydrophobic) state in response to a 
thermal stimulus around its volume phase transition temperature (VPTT) of ~33-35 oC.71 
This mechanical change due to the thermal stimuli has made these hydrogels useful for 
biological applications such as protein and cells detachment for tissue engineering, anti-
fouling coatings and self-cleaning membranes. To improve on its mechanical strength 
and rate at which the membrane swells and deswells, various modification of the 
fabrication method have been employed such as the addition of nanocomposites, the 
synthesis of double network hydrogels and the addition of comonomers. 
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Double network (DN) PNIPAAm hydrogels are known to be more mechanically 
robust. These hydrogels consist of interpenetrating polymer networks of two different 
degrees of cross-linked network. The enhanced mechanically properties that these gels 
provide can allow these hydrogels to be used as biocompatible, “self-cleaning”, 
implantable membranes that would stimulate little to no fibrous encapsulation by the 
immune response. Fei et al. introduced DN PNIPAAm hydrogels containing 
polysiloxane particles used to enhance the hydrogel’s thermosensitivity without altering 
its VPTT.72 Also, to shift the VPTT to ~38 oC which would allow for the membrane to 
be in the swollen hydrophilic state when implanted in the body,  N-vinylpyrrolidone 
(NVP) comonomer was introduced into the fabrication of these DN hydrogels.73, 74 Cell 
release studies have shown the detachment of cells of the surface of these modified DN 
hydrogels when the membrane is thermally cycled around body temperature.73 
Furthermore, the glucose diffusion coefficient at body temperature (35 oC) through these 
membranes are ~ 1.88 + 0.01 x 10-6 cm2/s which is comparable to the diffusion 
coefficient of glucose diffusion through the dermis and slightly faster than the diffusion 
through the epidermis.73, 75  
Recently, the DN PNIPAAm hydrogels were redesigned to replace the 
polysiloxane particles with AMPS because the particles only improved the 
thermosensitivity but not the hydrogel’s mechanical properties, with AMPS. Fei et al. 
showed that the inclusion of AMPS demonstrated improved both the thermosensitivity 
as well as the mechanical properties.76 Furthermore, the addition of the AMPS 
comonomer provided an overall negative charge of the membrane.76  This modified 
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hydrogel was evaluated in vitro and the incorporation of 25% AMPS and 75% AMPS 
were shown to be more favorable in disallowing cells to attached to its surface.77 
Moreover, the glucose diffusion through these hydrogels at body temperature remained 
relatively unaffected at 1.99 + 0.01 x 10-6  cm2/s for 25% AMPS hydrogels and slightly 
faster for 75% AMPS which exhibited a glucose diffusion coefficient of 2.21 + 0.02 x 
10-6.77  
Herein, 25% AMPS-PNIPAAm hydrogel was chosen for the use as the 
biocompatible housing chamber for the glucose sensing assay because of easy 
fabrication into a rod shape and concerns the biocompatibility of highly electrostatic 
charged materials in the body. However, in terms of encapsulation of nanoscale particles 
such as the glucose sensing assay, the large pores of hydrogels (60-200 µm) are 
problematic. This chapter aimed to show that directly injecting the assay into the AMPS-
PNIPAAm hydrogel rods would result in a decrease in FRET signal, in response to 
glucose, due to leaching of the assay from the hydrogel and thus resulting in the failure 
of sensor to sense glucose. Therefore, in order for AMPS-PNIPAAm to be used as a 
housing chamber for the glucose sensing assay various encapsulation techniques such as 
Layer by Layer, microspheres encapsulation or membrane immobilization needed to be 
employed in order to minimize leaching of the assay from the PNIPAAm membranes 
without greatly impacting glucose diffusion into the assay’s surroundings.  
 
 
 
  
53 
 
Synthesis of AMPS PNIPAAm Hydrogel Rods for Encapsulation 
The hydrogel rods were formed through a two-step, in situ photo-cure process. 
The single network (SN) copolymer precursor solution was synthesized with NIPAAm 
monomer, AMPS monomer (75:25 wt% NIPAAm:AMPS), BIS crosslinker, Irgacure-
2959 photoinitiator and DI H2O. In a 50 mL round bottom (RB) flask equipped with a 
teflon-covered stir bar, NIPAAm & AMPS (total weight of 1.0 g), BIS (0.04 g), and 
Irgacure 2959 (0.08 g) were dissolved in DI H2O (7.0 mL). The double network (DN) 
precursor solution was formed by combining NIPAAm (6.0 g), NVP (0.96 g), BIS 
(0.012 g), Irgacure 2959 (0.24 g), and DI H2O (21.0 mL). SN cylindrical hydrogels with 
a hollow center (outer diameter = 1 mm, inner diameter = 0.3 mm, length = 10 mm) 
were prepared by pipetting the SN precursor solution into a cylindrical glass mold (outer 
diameter = 1 mm, length = 10 mm) fitted with Teflon end caps and steel wire (diameter 
= 300 µm, inserted through the center of the caps) to create a centered hollow inner 
cavity. The mold was immersed in an ice water bath and exposed for 30 min to 
longwave UV light (UV-transilluminator, 6 mW cm-2, 365 nm). To remove hydrogels, 
Teflon caps were detached and molds were heated in the oven for ~20 min at 120 °C to 
dehydrate gels enough in order for them to slide out of the molds without fracture. The 
SN hydrogels were soaked in DI H2O for 2 days at RT and then transferred into the DN 
precursor solution to soak for 2 days at 2 °C. Next, a steel wire (diameter = 500 µm) was 
inserted into the hollow cavity of each cylindrical hydrogel (diameter larger due to 
swelling). The hydrogels were individually wrapped in transparent plastic wrap 
(SaranTM) then submerged in an ice water bath, exposed for 10 min to longwave UV 
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light, and soaked in DI H2O as above. A clean razor blade was used to trim ends to 
achieve a final geometry of 5 mm x 2.5 mm x 600 µm (length x outer diameter x inner 
diameter). 
 
Synthesis of AMPS PNIPAAm Hydrogel Membrane for Glucose Diffusion Studies 
The cylindrical membranes were formed through a two-step, in situ photo-cure 
process. The SN copolymer precursor solution was formed with NIPAAm monomer, 
AMPS monomer (75:25 wt% NIPAAm:AMPS), BIS crosslinker, Irgacure-2959 
photoinitiator and DI H2O. In a 50 mL RB flask equipped with a teflon-covered stir bar, 
NIPAAm & AMPS (total weight of 1.0 g), BIS (0.04 g), and Irgacure 2959 (0.08 g) were 
dissolved in DI H2O (7.0 mL). The DN precursor solution was formed by combining 
NIPAAm (6.0 g), NVP (0.96 g), BIS (0.012 g), Irgacure 2959 (0.24 g), and DI H2O 
(21.0 mL). SN rectangular sheet hydrogels were prepared similarly by pipetting the SN 
precursor solution into a rectangular mold consisting of 2 glass slides separated by 1 mm 
thick Teflon spacers. The mold was immersed in an ice water bath and exposed for 30 
min to UV light. The SN hydrogel was removed from the mold, soaked in DI H2O for 2 
days, and then transferred into the DN precursor to soak for 2 days at 2 °C. The gels 
were then sandwiched between 2 glass slides with 1 mm thick Teflon spacers enclosing 
the edges for support. The molds were immersed in an ice water bath and exposed for 30 
min to UV light. The DN hydrogels were removed from the mold and soaked in DI H2O 
as before. Final dimensions for the glucose study is 1 cm x 1 cm x 1 mm (length x width 
x thickness). 
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Encapsulation of Assay 
Different encapsulation techniques such as calcium carbonate, alginate 
microspheres and direct embedding via LbL were investigated to determine the 
encapsulation strategy that resulted in high loading efficiency, glucose 
diffusion/response and assay retention. Increasing the size of the competing ligand via 
PEGylation was also investigated to try and retain the assay components within the 
hydrogel rods. 
 
Direct Encapsulation 
The assay (10 µM mPEG-TRITC-ConA and 2 µM APTS-MT) was directly 
encapsulated into the AMPS-PNIPAAm hydrogel rods (~ 5mm in length) by pipetting 1 
µL of the assay into the hollow cavity and the ends were sealed with glass bead (710-850 
microns; Cospheric LLC) coated with ~98 wt% PEG (MW 575). The assay containing 
rods were then placed in wells of a 96 well-plate (Grenier, flat transparent) and a 
Tecan® Microplate reader was used to measure the FRET response in the presence of 
high concentration glucose (~1000 mg/dL).  
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Figure 14. The average glucose response of three FRET based biosensors after direct 
encapsulation of the assay (comprised 2 µM APTS-MT and 10 µM mPEG -TRITC-
ConA) in the AMPS-PNIPAAm rods indicating failure and inconsistency of the sensor 
to respond to high concentration of glucose due to leaching of assay components. 
 
Results showed that direct encapsulation of the assay resulted in a decrease in the 
FRET signal when glucose was introduced (Figure 14). This indicated failure of the 
sensor and it is due to the leaching of the assay components from the hydrogel 
membrane when glucose is introduced. The introduction of glucose replaced 
 APTS-MT at ConA’s binding site allowing the small molecules to be in its free 
state and due to size (~1 kDa; < 1nm) can then easily diffuse out of the membrane. 
Therefore there is a need to either increase the size of the assay or design a 
technique to indirectly encapsulate the glucose sensing assay either via the use of 
microspheres or modification to the AMPS-PNIPAAm membrane via LbL.  
 
 
  
57 
 
Calcium Carbonate Microspheres 
Layer by Layer deposition on calcium carbonate microsphere is one of the most 
commonly used method for various applications such as assay encapsulation for the 
design of nano/microsensors and drug delivery.78 This technique is desirable due to the 
easy fabrication method, high surface area, and easy dissolution of template under mild 
conditions and neutral pH; which would cause little to no harm to encapsulated materials 
such as proteins.79 Typically, calcium carbonate spheres self-assembles via co-
precipitation during the reaction of calcium chloride and sodium carbonate. 
Polyelectrolyte layers of alternating opposite charge can then be deposited on the surface 
of these spheres; which can function as both a housing chamber for the content being 
trapped and as a semi-permeable membrane for the diffusion of desired analytes into the 
spheres.80 After the deposition of the desired amount of layers, the core can then be 
removed by either ethylenediaminetetraacetic acid (EDTA), 2-ethanesulfonic acid 
(MES) or hydrochloric acid (HCl) which dissolves calcium carbonate into calcium ion 
and carbonate by-products. 
  Therefore, because of the simplicity of the fabrication method and the advantage 
of utilizing the layers as a diffusion membrane for glucose, this technique was 
investigated for the encapsulation of the glucose sensing assay. 
 The LbL calcium carbonate microspheres where fabricated based on previous 
work published by Dr. Michael McShane’s lab at Texas A&M University, where MES 
buffer was shown to be more effective in chelating the calcium core due to its low pH.81 
Furthermore the (PVSA) poly (vinyl sulfonic acid) was used in the fabrication method to 
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produce stable vaterite polymorph calcium carbonate spheres; which are said to be more 
water soluble and easier to dissolve.81 However, because ConA is a protein, this MES 
buffer may have an effect on denaturing the protein or deactivating its binding site. 
Therefore, the activity of mPEG-ConA was first investigated to ensure that the MES 
buffer would fully dissolve the core without affecting the binding functionality of the 
protein.  
Briefly, mPEG-ConA in 0.2 M Na2CO3 buffer (1 mL) was added to a beaker and 
stirred at 800 RPM for 1 min. Next, 1 mL of 0.2M CaCl2 was quickly added to the 
solution and after 1 min the speed was reduced to 600 RPM. After 10 min, 50 µL of poly 
(vinyl sulfonic acid) PVSA was added and stirred for another 5 min. The particles were 
then spun down at 1000g for 2 min and the supernatant was removed. To determine the 
activity of the encapsulated mPEG-ConA, the CaCO3 was dissolved by washing the 
microspheres two times in a 3K Microsep with 0.25 M MES buffer (pH 6.1). Three more 
washes were then performed with TRIS buffer. The concentration of mPEG-ConA was 
determine via absorbance at 280 nm measured on UV-VIS spectrometer. Fluorescence 
anisotropy, conducted similar to before, was then used to determine the binding affinity 
of the mPEG-ConA to APTS-MT (Equation 3). 
Results showed that the binding affinity of the encapsulated mPEG-ConA was 
7.41 x 106 M which is similar and on the same order to the binding affinity reported in 
previous work.82 Therefore, the affinity was not significantly affected when MES buffer 
was used to chelate the calcium core. This was further verified via scanning electron 
microscopy/energy dispersive X-ray spectroscopy (SEM/EDX) image in Figure 16 
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which showed no presence of calcium residues after the dissolution of the calcium 
carbonate core (Figure 16). 
 
 
Figure 15. Scanning electron microscopy image of LbL calcium carbonate microspheres 
after treatment with MES buffer to remove calcium carbonate core. The collapsed walls 
indicate the absence of the core. 
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Figure 16. Energy dispersive X-ray spectrum indicating the absence of calcium ions 
confirming the removal of the calcium carbonate core after treatment with MES buffer. 
 
Next, the complete FRET based glucose sensing assay was encapsulated within 
LbL CaCO3 microspheres. The CaCO3 microspheres were prepared similar to above 
with the 1 mL of the assay (23 µM mPEG-TRITC-ConA and 400 nM APTS-MT) 
dissolved in Na2CO3 buffer. Before the core was dissolved with MES buffer, eight 
bilayers of PDADMAC+/PSS- were deposited on the surface of the microspheres in 
order to create a semi-permeable membrane that would retain the assay but allow 
glucose to diffuse into the core.  Then similar to before, the CaCO3 microspheres core 
was dissolved by washing the microspheres three times in a 3K Microsep with 0.25 M 
MES buffer (pH 6.1). The spheres were re-suspended in TBS buffer. Fluorescence 
microscopy images (Figure 17) confirmed that both assay components were distributed 
throughout the LbL calcium carbonate templated microspheres (~ 3µm).  
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Figure 17. Fluorescence images of the assay (A) APTS-MT and (B) mPEG-TRITC-
ConA after encapsulation in ~ 3 µm LbL calcium carbonate templated microspheres. 
 
To test the performance of the microspheres within the AMPS-PNIPAAm 
hydrogel rods, the microspheres were pipetted into the hollow AMPS-PNIPAAm rods (~ 
5 mm in length) and packed to capacity (~1 µL volume of spheres). The rods were then 
capped with glass beads coated in ~98 wt% PEG (MW 575). The glucose response data 
showed a change in FRET signal of ~16% with increasing glucose concentration from 0 
mg/dL to 400 mg/dL.  
 
A B 
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Figure 18. FRET response of the assay encapsulated within LbL calcium carbonate 
templated microspheres indicating a change in FRET signal in the prescence of varying 
concentration of glucose within the physiological relevant range. 
 
Although promising, these results were not repeatable (Figure 19) within the 
same batch of microspheres. This may be due to inhomogeneity issues. Also another 
limitation is the high initial concentration of assay required and an estimated low loading 
efficiency (less than 15%). 
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Figure 19. Repeated FRET response from the same batch of the assay encapsulated 
within LbL calcium carbonate templated microspheres indicating no change in FRET 
signal in the prescence of varying concentration of glucose within the physiological 
relevant range. 
 
 
Alginate Microspheres 
Another commonly used encapsulation method for the design of biosensors is 
alginate LbL microspheres. Different research groups have utilized this method for the 
encapsulation of fluorescence based sensing assays due to its easy and mild fabrication 
method which would result in little to no harm to sensitive molecules such as proteins.83, 
84 Therefore this technique was investigated next as a potential indirect 
microencapsulation of the glucose sensing assay. The assay containing microspheres 
were fabricated by Dr. Michael McShane’s research group at Texas A&M University.  
Briefly, 500 µL of the glucose sensing assay (10 µM mPEG-TRITC-ConA and 2 
µM APTS-MT) in TBS was mixed with 3.8 mL alginate solution (3%). This solution 
was then added to 7.5 mL of Span-85/iso-octane solution and allowed to mix via a 
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homogenizer at 8,000 RMP for two minutes. Next, 1 mL of TWEEN-85 solution was 
added to the emulsion and allowed to continue mixing for another minute. Calcium 
chloride solution (10% w/v) was then pipetted into the emulsion and the homogenizer 
was turned off. The emulsion was then transferred to an RB flask and allowed to mix on 
a magnetic stir plate for 20 minutes. The particles were then spun down at 2000g to form 
a pellet. The supernatant was then removed and the particles were washed three times 
with DI H2O. Immediately following synthesis, 10 bilayers of PAH
+/PSS- was deposited 
on the microspheres surface using standard LbL technique. The assay containing 
alginate calcium LbL microspheres were then re-suspended in TBS. 
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Figure 20. (A) Bright-field and Fluorescence images of the assay (B) 2 µM APTS-MT 
and (C) 10 µM mPEG-TRITC-ConA after encapsulation in LbL alginate-calcium 
microspheres.  
 
The fluorescence images showed that assay contained within the microspheres 
which had an average diameter of 5 to 10 µm (Figure 20). To test the glucose response, 
different volumes of spheres (10 µL, 20 µL, 50 µL and 100 µL) in TBS were pipetted 
into a 96 well-plate (Corning) and fluorescence emission measurements were taken from 
480 nm to 680 nm with an excitation of 450 nm. Next, glucose was added to each well 
for a final concentration of 600 mg/dL and fluorescence measurements were taken after 
30 minutes of incubation.  
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Once again the glucose response data showed little to no change in FRET signal; 
less than 3% across physiological relevant glucose range (Figure 21). Furthermore, the 
high concentration of assay required and unknown loading efficiency due to high 
dilution factor made it difficult to optimize the fabrication method to try and improve the 
FRET efficiency. 
 
 
Figure 21. The average FRET response of the assay encapsulated within LbL alginate-
calcium microspheres indicating little to no change in FRET signal in the prescence of 
varying concentration of glucose within the physiological relevant range. 
 
 
Increasing APTS-MT Size via PEGylation 
The size of APTS-MT is ~1 kDa (< 1 nm), therefore to increase its size and the 
potential for it to be retained within the biocompatible membrane the technique of 
PEGylation was explored. The fluorophore APTS has three potential functional groups 
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(3x sulfonyl chloride) that can be utilized for the conjugation of short PEG chains 
(Figure 22). 
 
 
Figure 22. Schematic of the native structure of the donor fluorophore, 8-aminopyrene-1, 
3, 6-trisulfonyl chloride. 
 
 The synthesis of this bulked up APTS-MT was conducted by Dr. Gabbai’s 
research group at Texas A&M University. Briefly, PEG chains (MW 2 kDa) were 
attached to the fluorophore based on the following reaction where 0.015 mmol of the dye 
(compound 1) was dissolved in CH3CN (0.50 mL) followed by the addition of a 0.046 
mmol PEG-amine (H2N-PEG) and 0.057 mmol disopropylethylamine (DIEA) (Figure 
23). The solvent was then removed under reduced pressure and the residue was 
redissolved in DI H2O (1.00 mL). 
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Figure 23. Synthesis of PEGylated APTS to increase the size of the competing ligand by 
increasing the apparent size of the donor fluorophore via the addition of three PEG chains 
(MW 2 kDa). 
 
 
 The excess PEG-amine was removed via dialysis and absorbance was used to 
confirm the presence of the PEG chains (Figure 24). It is expected that the addition of 
each PEG chain would result in ~7 to 10 nm wavelength redshift. A 50 nm wavelength 
shift was observed after the addition of the PEG chains to the dye (Figure 24). This 
confirmed the presence of the PEG chains.  
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Figure 24. Absorbance spectroscopy scan indicating an approximate 50 nm wavelength 
shift after the addition of the PEG chains. 
 
 Following the conjugation of the dye, mannotetraose was conjugated to the free 
aromatic amine group on the newly PEGylated dye (Figure 25). Briefly, 0.0010 mmol of 
the PEGylated dye was dissolved in 15% acetic acid (AcOH) aqueous solution (0.20 
mL). Next, 0.0015 mmol of mannotetraose was added to the solution and 0.50 mL of 
15% AcOH aqueous solution was added to the mixture. The solution was then stirred at 
room temperature for 10 min and then 0.0160 mmol sodium cyanoborohydride 
(NaBH3CN) dissolved in 0.30 mL tetrahydrofuran (THF) was added to the mixture. The 
reaction mixture was then stirred at room temperature for 15 h. 
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Figure 25. Synthesis of PEGylated APTS-MT via reductive amination to increase the size 
of the ligand with a single fluorophore and three PEG chains. 
 
 A HiTrap ConA column was then used to purify the sample after dialysis was 
used to remove the unbound mannotetraose. Absorbance measurements were taken to 
confirm presence of the conjugated sugar which was expected to result in an additional 
20 nm wavelength redshift if present. It was observed from Figure 26 that the only a 4 
nm wavelength shift occurred. Furthermore, this solution was not able to bind to the 
ConA column indicating that either the sugar was not conjugated successfully or the 
PEG chains were hindering binding of the sugar to ConA or the conjugation of the sugar 
to the dye. 
 
  
71 
 
 
Figure 26. Absorbance spectroscopy scan after the conjugated of the competing ligand, 
mannotetraose, indicating no apparent shift in wavelength. 
 
Therefore, an attempt was made to conjugate mannotetraose to the APTS dye 
prior to the addition of the PEG chains. A 20 nm wavelength shift was observed which 
indicated the presence of mannoetraose (Figure 27).  
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Figure 27. Absorbance spectroscopy scan after the conjugated of the competing ligand 
followed by the PEGylation of the fluorophore indicating a significant shift in 
wavelength. 
 
Based on these results it was concluded that although PEGylation of APTS is 
possible the free steric hindrance of the chains did not allow for the successful 
conjugation of the competing ligand, mannotetraose and could potentially hinder the 
binding of the ligand to ConA. However, the potential to conjugate the PEG chains to 
the dye could play a significant role in the immobilization of APTS-MT to the walls of 
the AMPS-PNIPAAm rods which was investigated and described in a later section of 
this work. 
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Layer-by-Layer on PINIPAAm Inner Wall 
Directly embedding the assay within the AMPS-PNIPAAm hydrogel rod is 
desirable because the loading efficiency of the assay can be controlled. This can be 
achieved by utilizing LbL, similar to the previous microencapsulation technique, where 
the bilayer can potentially serve as a semipermeable membrane. 
 The poly-electrolytes used were prepared at pH 8 in 5 mM sodium bicarbonate 
buffer: PDADMAC+ (2 mg/mL), PSS- (2 mg/mL), and RITC-PAH+ (2 mg/mL). The 
hydrogel was then connected to inlet and outlet needles as shown in Figure 18. Next, the 
inner surface of the hydrogel rod synthesized above was washed by flowing 5 mL of DI 
H2O through the gels three times, via a 5 mL syringe. For imaging purposes, 5 Bilayers of 
RITC-PAH+/ PSS- was deposited on the inner wall of the hydrogel rod. RITC-PAH+ allow 
for the imaging of the layers via fluorescence microscopy. Briefly, 1 mL of RITC-PAH+ 
was deposited first on the inner walls of the hollow rod hydrogel since its overall charge 
is negative. After 1 minute, 5 mL of DI H2O was injected into the rod to wash away any 
residues that did not attach electrostatically to the wall. Following this wash, 1 mL of PSS- 
was injected in a similar manner into the rod and after allowing it to interact with the 
previous layer for 1 minute the inner walls were again washed with 5 mL of DI H2O. This 
was repeated until all 5 bilayers were deposited; then the rod was washed 3 times with DI 
H2O. Bright-field and fluorescence images were then taken via a Nikon Eclipse TE2000-
U Inverted Microscope (Nikon Instruments Inc., Melville, NY). A hydrogel without layers 
was also imaged under the same microscope as a control. 
 
Inlet 
needle 
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Figure 28. Schematic of LbL experimental set-up. 
 
The fluorescence image in Figure 19 showed that the poly-electrolyte layers 
adhered to inner wall of the hydrogel. Furthermore, based on the absence of fluorescence 
within the walls of the hydrogels, we can conclude that the poly-electrolytes did not diffuse 
into the walls of the hydrogel rod.  
 
 
Figure 29. Fluorecence image of the LbL layers within the inner channel of the AMPS-
PNIPAAm. Fluorescence is due to the Rhodamine dye conjugated to the positively 
charged polyelectrolyte, PAH+. 
 
 
Inlet 
needle Outlet 
needle 
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For the purpose of glucose response hydrogels rods were prepared in a similar 
manner but with only six bilayers of PDADMAC+/PSS-; since a minimum of five bilayers 
are needed for layer stability. The assay was then encapsulated by pipetting of 1 µL of 
assay (10 µM mPEG-TRITC-ConA and 2 µM APTS-MT) into the rod and capping both 
ends with glass beads sealed with 98% PEG (mw 575). Preliminary FRET response 
(Figure 30) showed a FRET increased of ~49% in response to physiologically relevant 
glucose concentration (600 mg/dL). This is an improvement over both the calcium 
carbonate and the alginate based microencapsulation techniques as well as previous direct 
encapsulation method when there was a negative FRET response as assay leached out in 
the absence of the layers.  However, further characterization of this method in terms of 
assay leaching and glucose diffusion need to be conducted in order to determine the 
appropriate number of bilayers needed to retain the assay without hindering glucose 
diffusion. 
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Figure 30. Glucose response of glucose biosensor after encapsulation of the assay (2 µM 
APTS-MT and 10 µM mPEG -TRITC-ConA) in the AMPS-PNIPAAm rods containing 
6 bilayers on its inner wall. 
 
 
Leaching and Glucose Diffusion Studies 
From the different encapsulation and modification techniques investigated above, 
LbL proved to be more efficient in the ability to control concentration and loading 
efficiency, achieving glucose response of the encapsulated assay and in its easy 
fabrication. Therefore, this method was selected for further investigation in the 
development of the glucose biosensor. 
 
Leaching Studies 
To determine if LbL can be used to minimize leaching from the porous AMPS-
PNIPAAm hydrogels, a 24 h leaching study was conducted using varying amount of 
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polyelectrolyte bilayers deposited on the inner walls of the hollow rod. Then the 
exposure of the biosensors to high concentration glucose (1000 mg/dL) allowed for the 
majority of the assay’s components to be in their unbound state, due to the competitive 
binding of glucose to ConA freeing APTS-MT from its binding site. Since APTS-MT is 
the smaller component (~1 kDa), it would be more likely to leach out of the membrane 
compared to mPEG-TRITC-ConA (~104 kDa).   
The supernatant data showed a decrease in APTS-MT leaching with increasing 
number of bilayers (Figure 31). 75-80% of APTS-MT was retaining within the 
membrane after at least 30 Bilayers were deposited on the inner wall of the AMPS-
PNIPAAm hydrogel rods.  
 
 
Figure 31. Fluorescence leaching study of encapsulated APTS-MT for varying bilayers 
of PDADMAC/PSS on the inner wall of AMPS-PNIPAAm hydrogel rods. 
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A more detailed leaching study comparing 0 bilayers versus 30 bilayers was 
conducted to show the improvement that the presence of the 30 bilayers provides. Figure 
32 shows that within the first 12 h the hydrogel rods without the layers experienced a 
more significant leaching of APTS-MT when compared to the 30 bilayer rods.  
 
 
Figure 32. The average fluorescence intensity of the supernatant for three assay 
containing hydrogel rods exposed to high concentration glucose to compare the amount 
of leaching of APTS-MT from rods modified with 0 and 30 bilayers. 
 
Although this is a significant improvement because without the layers almost all 
APTS-MT leached out after being displaced by a high concentration of glucose, this is 
still not sufficient in designing a long term implantable glucose sensor. Therefore, 
further modification via immobilization of APTS-MT on the inner most layer can be 
explored in order to try and fully retain the assay components.  It should also be noted 
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less than 10% of the mPEG-TRITC-ConA leached out the rods regardless of the number 
of bilayers (Figure 33). This suggest that there is a greater need to modify the 
encapsulation method based on the competing ligand instead of the lectin. 
 
 
Figure 33. The average fluorescence intensity of the supernatant for three assay 
containing hydrogel rods exposed to high concentration glucose to compare the amount 
of leaching of mPEG-TRITC-ConA from rods modified with 0 and 30 bilayers. 
 
 
Glucose Diffusion Studies 
The purpose of these layer-by-layer (LbL) hollow rod hydrogels is to act as a 
biocompatible housing chamber for a glucose sensing assay and a semi-permeable 
membrane for glucose diffusion. Therefore, glucose diffusion studies were conducted 
body temperature (35 oC) on hydrogels with a range of bilayers (# of bilayers: 0, 10, 20 
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and 30) to determine whether the presence of the layer hindered the diffusion rate of 
glucose through the gel.  
For this study, approximately 1.5 mm thick 25% AMPS PNIPAAm hydrogel 
slabs was synthesized. Using an open-face filter holder (Pall Co., Port Washington, NY), 
the hydrogel slab was securely clamped between the ring which allowed for only one 
side of the hydrogel to be exposed for LbL modification. The exposed side was washed 
3 times with 10 mL DI H2O and then the bilayers of PDADMAC
+/ PSS- were deposited 
on its surface, in similar manner to above. The hydrogel was then removed from the 
filter holder and the side with the layers was marked as a means of identification in the 
future. The hydrogel membranes were then allowed to soak in DI H2O for 24 hours 
before diffusion tests were performed.  
The LbL hydrogel was then cut into smaller strips (1cm x 1cm) and placed in 
side-by-side diffusion chambers (PermeGear, Bethlehem, PA) with the LbL side facing 
the receiver chamber containing 3 mL DI H2O. The donor chamber contained 3 mL 
glucose solution (~1000 mg/dL). The chambers were mounted on a stir plate set to 1000 
rpm to ensure that the concentration in both chambers remained constant. The diffusion 
chambers were connected to a water bath pump system set to 35 oC. 
 In 20 min intervals, 50 µL of solution was extracted from each chamber via a 
pipette for a period of 3 hours. An YSI 2300 Stat Plus Biochemistry Analyzer (YSI Inc., 
Yellow Springs, OH) was then used to determine the concentration of glucose present in 
the extracted samples. Then the diffusion coefficient was calculated using the following 
derivative form of Fick’s second law of diffusion (Equation 9): 
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𝜕𝑐
𝜕𝑡
= 𝐷 
𝜕2𝑐
𝜕𝑥2
 
Equation 9. 
 
Where c is the concentration within the receiving chamber, t is the time, D is the 
diffusion coefficient and x is the diffusion distance. Under the assumption that each 
chamber maintained a uniformed concentration, Equation 9 was simplified to: 
 
𝑄𝑡 =
𝐴𝐷𝐶𝑖
𝑇
 (𝑡 −
𝑇2
6𝐷
) 
Equation 10. 
 
Where Qt is the amount of glucose transferred through the membrane at a specific 
time, t. A indicates the area of the hydrogel exposed to either the donor or receiver 
chamber and Ci is the initial stock glucose concentration within the donor channel at t 
equal zero. T is the thickness of the hydrogel membrane. 
 
Table 1. Comparing the glucose diffusion coefficient for AMPS-PNIPAAm hydrogel 
membranes modified with different number of bilayers. 
 
Hydrogel Composition Glucose Diffusion Coefficient cm2 s-1 
DN PNIPAAm Nanocomposite 1.88 x10-6 + 0.001 
DN 25% AMPS no layers 2.61 x10-6 + 0.13 
DN 25% AMPS 10 Bilayers 2.68 x10-6 + 0.41 
DN 25% AMPS  20 Bilayers 2.20 x10-6 + 0.02 
DN 25% AMPS 30 Bilayers 2.43 x 10-6 + 0.13 
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Results indicated that the presence of the layers did not significantly hinder the 
diffusion of glucose through the hydrogel membranes when compared with hydrogel 
membranes consisting of no layers. 
 
Glucose Response  
  The glucose response of the assay containing AMPS-PNIPAAm rods were 
evaluated within physiologically relevant glucose concentration (0 to 600 mg/dL) to 
determine its functionality, time response, sensitivity. These hydrogels were initially 
evaluated at room temperature.  
 
Time Response Study 
The time response of the biosensors was evaluated using a Tecan Microplate 
Reader. Hydrogel rods (length: (~5 mm) modified with 30 bilayers and containing 1 µL 
of the glucose assay (2 µM APTS-MT and 10 µM mPEG-TRITC-ConA) were each 
placed within a well of a 96-well plate and submerge in 200 µL of TBS solution. An 
initial fluorescence scan was taken to determine the FRET signal at 0 mg/dL. Next, the 
concentration of the solution was increased to 600 mg/dL using a stock concentration of 
glucose (~50, 000 mg/dL). Fluorescence measurements (λem range: 480 nm to 680 nm) 
were taken every 10 minutes until the signal stabilized. 
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Figure 34. The average time response of three 30 bilayer AMPS-PNIPAAm hydrogel 
rods containing 1 µL of the glucose sensing assay (2 µM APTS-MT and 10 µM mPEG-
TRITC-ConA) in the presence of 600 mg/dL glucose concentration. 
 
Figure 34 indicated that the FRET signal reached stability after approximately 30 
minutes. Ideally the time response goal is approximately 5 to 10 minutes. Based on the 
LbL glucose diffusion data (Table 1) the presence of the layers does not play a 
significant role in the sensors response time. Therefore, one potential solution to 
increasing the response time would be to increase the porosity of the AMPS-PNIPAAm 
membrane. 
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Glucose Response Sensitivity Study 
Thus far the glucose biosensor has only been evaluated at the high concentration 
of the physiological relevant range. Therefore, this study aimed to investigate the 
sensitivity of the sensor for concentrations within this range (0 to 600 mg/dL). AMPS-
PNIPAAm rods containing the assay were prepared similarly to previous method where 
1 µL of the assay were encapsulated within the 30 bilayers rods. Fluorescence 
measurements were taken for each glucose concentration after 15 minutes wait time. 
 
 
Figure 35. The average FRET response of three 30 bilayer AMPS-PNIPAAm hydrogel 
rods containing 1 µL of the glucose sensing assay (2 µM APTS-MT and 10 µM mPEG-
TRITC-ConA) in the presence of varying concentrations of glucose (0 to 600 mg/dL) 
within the physiological relevant range. 
 
Figure 35 shows that the biosensors can track changes in glucose concentrations. 
This data was fitted to a typical competitive binding curve and the predicted versus 
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actual glucose concentration plot was obtained (Figure 36). This results indicated that 
the assay can track changes in glucose concentration with a MARD of ~10 + 0.9%. This 
MARD is comparable to the CGM devices proposed by various research groups whose 
in vivo MARD% ranged from 11% to 16%.16-18 
 
 
Figure 36. Preliminary result showing predicted versus actual glucose response of three 
30 bilayer AMPS-PNIPAAm assay containing hydrogel rods showing ability to predict 
changes in glucose concentrations with a MARD around 10%. 
 
Long Term Glucose Response Study 
The lifetime of current commercially FDA approved CGM device is three to 
seven days. Therefore, the proposed glucose sensor within this work was evaluated to 
determine its response over a week.  Fluorescence measurements were taken each day 
for seven days for glucose concentrations at 0 mg/dL (TBS only) and 600 mg/dL.  
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Figure 37. The average glucose response of three biosensors over seven days to 
determine its longevity. 
 
Results indicated that the sensor has the ability to sense glucose up to 2 days 
(Figure 37). However, after the first day a decrease from 56% to 39% in the FRET signal 
was observed and the signal continued to decrease over the course of 7 days. This result 
indicates the need for further improvement on the LbL technique to improve on the 
retention of the assay within the AMPS-PNIPAAm hydrogel rod. This can be 
accomplished in two ways by either crosslinking the polyelectrolyte layers within the 
LbL or by immobilizing the APTS-MT on the layers.  
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CHAPTER V  
IMMOBILIZATION OF APTS-MT ON INNER WALL OF AMPS-PNIPAAM  
 
From the leaching studies above it was observed that only 75-80% of the assay 
was retained in the membrane after 24 h. This is not ideal when aiming to develop a long 
term implantable sensor. APTS-MT, the smaller component of the assay, had a higher 
percentage of leaching compared to mPEG-TRITC-ConA. Using the same LbL 
technique, an alternative negatively charged polyelectrolyte, poly (4-styrenesulfonic 
acid-co-maleic acid) sodium salt (PSS-co- maleic acid), can allow for APTS-MT to be 
immobilized on the layers via a PEG linker chain (NH2-PEG800-NH2; Nanocs) and 
similar to the techniques used when attempting to bulk up of the molecule. 
 
Immobilization of APTS-MT 
For the LbL, 10 bilayers of PDADMAC/PSS-co-maleic aid was deposited on the 
inner wall of the AMPS-PNIPAAm rods. These PSS-co-maleic acid layers provide free 
carboxylic acid functional groups that can be used to bind amine reactive groups to it. In 
this work bifunctional PEG-amine (PEG MW 800 Da) was attached to these free 
carboxylic groups using a standard NHS/EDC reaction. Following the addition of the 
bifunctional PEG linker the CL dye in the form of 2-acrylamido-2-methylpropane 
trisulfonyl chloride was allowed to react with the free amine of the linker via the same 
chemical reaction used in the synthesis of bulk up APTS-MT described in Figure 23.  
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The presence of the immobilized dye was confirmed via Fluorescence images 
(Figure 37) after washing at least five times with DI H2O and soaking in DI H2O 
overnight to remove any free dye. 
 
 
 
Figure 38. (A) Bright field image and (B) Fluorecence image of immobilized the donor 
fluorophore, APTS, via LbL layers within the inner channel of the AMPS-PNIPAAm.  
 
 An attempt was then made to conjugate mannotetraose to the immobilized dye 
using the Prozyme® Amine Reduction that was previously used to synthesize APTS-
Dextran. The excess/unconjugated dye was removed via several DI H2O washes and 
absorbance measurements were taken to determine the excitation wavelength of the 
immobilized molecule as a means to determine the success of the reaction. It is expected 
that the peak absorbance wavelength should shift from ~420 nm to ~450 nm from the 
conjugation of the dye alone to the dye bound to mannotetraose which was confirmed by 
A 
B 
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absorbance scan on the hydrogel rod. This method requires further optimization to obtain 
the desired molar concentration of APTS-MT conjugated to the LbL wall for the next 
generation to be able to sense changes in glucose concentrations. 
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CHAPTER VI  
SUMMARY AND FUTURE WORK 
 
In summary, the goal of this research was to design and encapsulate a thermally 
stable, non-aggregative ConA-based competitive binding assay, towards the overall goal 
of producing a continuous glucose monitoring biosensor. 
Previous work used native unbound ConA as the glucose receptor. The assays 
generated with this ConA resulted in constant aggregation of ConA and inconsistency in 
the assay’s sensitivity to glucose.  Furthermore, previous assay contained the use of 
competing ligands such as dextran and glycosylated dendrimer. Even though these two 
competing ligands demonstrated response to glucose when tested with physiological 
relevant concentrations, the extent at which their assays fluorescence changed in 
response to glucose was either small or inconsistent. Therefore, there was a need to 
investigate an alternative assay composition to improve its sensitivity and overcome 
these problems. Recent work had introduced a new competing ligand, mannotetraose, as 
a means to improve the assay’s sensitivity. Therefore, there was a need to characterize 
the new assay’s sensitivity and stability. Also, prior to this date the functionality of this 
assay within the designed biocompatible membrane was not yet determined due to the 
need to further characterize the membrane’s biocompatibility, cell toxicity and 
mechanical properties. Therefore, this work aimed to encapsulate and characterize the 
assay’s functionality within this membrane. 
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It was determined that PEGylation of ConA would aid in the stability of the 
protein at body temperature minimizing the chances of the protein undergoing thermal 
unfolding and aggregation. This work also noted that the use of PEGylation did not 
hinder ConA’s ability in binding to a competing ligand and its performance within a 
competitive binding assay to sense changes in physiologically relevant glucose 
concentrations. Thus generating a thermally stable glucose sensing assay. 
The characterization of the competing ligand, mannotetraose, showed that this 
new ligand did not produce large aggregates when bound to ConA unlike the traditional 
ligand, dextran. Furthermore, mannotetraose proved to be more sensitive to changes in 
glucose concentration, over dextran, when placed within FRET based competitive 
binding system.  
This work was the first to incorporate the assay within the biocompatible 
PNIPAAm based hydrogel rod and showed that the assay can still sense glucose within 
the physiological concentration range. A major obstacle to overcome was the size of the 
assay (nanoscale) versus the pore size of the hydrogel (microscale). To address this 
problem, various encapsulation techniques that are traditionally used to encapsulate 
nanoscale assays were investigated as well as the possibility of increasing the size of the 
smaller assay component, APTS-MT. It was determined that the best method for 
encapsulation would be to deposit LbL on the inner walls of the hydrogel rods and then 
directly inject the assay into the hollow cavity. This method allowed for the control of 
the loading efficiency, concentration and volume of assay used without significantly 
affecting the functionality of the assay. Although this technique provided improved the 
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retention of the assay inside the hydrogel rod, as a long term sensor there is still need for 
improvement as it was observed that over a week the change in FRET signal dropped 
due to leaching of the smaller assay component. 
Future work involves the design and characterization of a second generation 
biosensor which contains the competing ligand immobilized on the LbL wall of the 
biocompatible hydrogel rods in the hopes of producing a long term glucose biosensor. 
This is currently being investigated in the Optical Biosensing Lab. In addition, new 
FRET pair fluorophores could be chosen which excites and emits further into the red 
wavelength range. This is needed to minimize the background noise from the tissue’s 
optical properties. 
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